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ABSTRACT 
 
Rachel Palmieri Weber: Evaluation of hysterectomy as both exposure and outcome: Association with 
epithelial ovarian cancer and prediction of premenopausal hysterectomy with ovarian conservation 
(Under the direction of Andrew F. Olshan) 
 
 Hysterectomy is the most common non-obstetric, surgical procedure among women in the 
United States. Older studies have generally reported that hysterectomy is inversely associated with 
risk of epithelial ovarian cancer (EOC). One of the goals of this dissertation was to investigate this 
relationship, focusing on subtypes of EOC. Since a majority of ovarian-conserving hysterectomies 
occur prior to menopause, we also sought to develop a predictive model for premenopausal 
hysterectomy with ovarian conservation as a way of identifying traits that may help identify women 
for clinical monitoring and potentially earlier and less invasive treatment than hysterectomy for their 
conditions. 
 We estimated study-specific odds ratios by conditional logistic regression for almost 30,000 
EOC cases and controls from 15 studies in the Ovarian Cancer Association Consortium and pooled 
them using random-effects models. Hysterectomy was associated with an average relative increase of 
19% in the odds for invasive EOC. The average odds ratios were above the null for all subtypes of 
EOC, except invasive clear cell. Hysterectomies prior to age 40 or 30 years or more in the past were 
also positively associated with invasive serous EOC. 
 We also fit unconditional logistic regression models including fourteen demographic, 
behavioral, and reproductive and medical history variables to nearly one thousand premenopausal 
women with and without hysterectomy enrolled in the Prospective Research on Ovarian Function 
Study. The predictive model exhibited very good discriminatory power and was well-calibrated. 
Family history of benign gynecologic conditions did not contribute to the prediction model and in 
fact, resulted in a net worsening of classification of hysterectomy.  
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 Our results, from the largest set of EOC cases and controls to date, do not support the long-
held belief that hysterectomy is protective against EOC. Considerable heterogeneity of results, 
potential biases in previous and/or current studies, and/or a changing association between 
hysterectomy and EOC may explain our results and should be explored further. Though we were able 
to predict premenopausal hysterectomy with ovarian conservation with very good discriminatory 
power, additional model development should be pursued in larger and more diverse populations of 
premenopausal women as we try to better understand premenopausal women who undergo 
hysterectomy. 
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CHAPTER 1. INTRODUCTION 
1.1 Motivation for dissertation 
 The Ovarian Cancer Association Consortium (OCAC) was originally formed in 2005 to 
combine data from multiple, established studies of ovarian cancer, primarily of case-control design, in 
an effort to validate ovarian cancer susceptibility polymorphisms. These large-scale, collaborative 
efforts include centralized high-throughput genotyping and functional biology experiments, data 
management, and analysis. Because of the wealth of data on known and suspected epidemiological 
risk factors for ovarian cancer that is available from numerous member studies, the OCAC is also in 
the position to evaluate known and suspected epidemiological risk factors for histopathological 
subtypes of ovarian cancer. These subtype-specific analyses were previously difficult to do because 
of small sample sizes within any one given study and within specific ovarian cancer subtypes. 
 Though the long-established literature has reported an inverse association between 
hysterectomy and epithelial ovarian cancer, epidemiologists within the OCAC were not finding a 
higher prevalence of hysterectomy among controls in their respective studies as they analyzed other 
exposures of interest. Additionally, there were no evaluations of the association between 
hysterectomy and histopathological subtypes of epithelial ovarian due to the rarity of ovarian cancer 
overall and even smaller frequencies of certain subtypes. To that end, we proposed an evaluation of 
hysterectomy in 15 case-control studies in the OCAC that would be the largest analysis of individual-
level data, to date, of the association between hysterectomy and subtypes of epithelial ovarian cancer. 
 Because our findings were not consistent with the long-held belief that hysterectomy and 
ovarian cancer were inversely associated, we sought data that could help us better describe 
premenopausal hysterectomies with ovarian conservation (the majority of hysterectomies in the 
OCAC analysis). To that end, we proposed the development of a multivariate prediction model for 
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hysterectomy with ovarian conservation among premenopausal women in Prospective Research on 
Ovarian Function (PROOF): A Study of Hormonal Changes in Premenopausal Women. 
1.2 Dissertation layout 
 This dissertation includes six chapters. This introductory chapter orients the reader to the 
motivation behind the doctoral work and organization of the dissertation. Chapter 2 details the review 
of the literature on hysterectomy, ovarian cancer, and the associations between them. Chapter 3 
outlines the data sources and analytic plan for each of the two sets of specific aims that focus first, on 
hysterectomy as an exposure and second, on hysterectomy as an outcome. Because hysterectomy is 
the exposure for one set of specific aims, and the outcome for another set of specific aims, the 
analytic plans are presented separately and correspond with the results in Chapters 4 and 5, 
respectively. Chapters 4 and 5 present those results in the format of two separate research 
manuscripts. Chapter 6 recapitulates the specific aims and findings, outlines the strengths and 
limitations of the analyses, briefly discusses the public health significance of the work, and provides 
suggestions for future research related to hysterectomy. 
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CHAPTER 2. REVIEW OF THE LITERATURE 
2.1 Hysterectomy 
2.1.1 Epidemiology of hysterectomy 
 Hysterectomy is the most common non-obstetric, surgical procedure among women in the 
United States (US).
1
 Approximately 600,000 hysterectomies are performed each year in the US and 
more than one-third of women will have a hysterectomy by age 60.
2,3
 The hysterectomy rate in the US 
peaked in 1975, when more than 725,000 were performed, declined through the 1980s, leveled off in 
the 1990s, and decreased only slightly each year between 1997 and 2005;
2-6
 the incidence of age-
adjusted hysterectomy was 6 per 1000 women in 1997 and by 2005, 5 per 1000 women.
2 
Hysterectomy rates and prevalence appear to be lower across the globe than they are in the 
US. In Australia, 20% of women have a hysterectomy by age 50. The prevalence of hysterectomy is 
between 10% and 22% based on Australian surveys
7
 and 30,000 hysterectomies are performed 
annually.
8
 The prevalence of hysterectomy is less in the United Kingdom (UK) than in the US or 
Australia and has not changed since 1996.
9
 Rates are even lower in Denmark. The incidence rate of 
hysterectomy in 1988 in Denmark was 193 per 100,000 women and dropped to 170 per 100,000 
women by 1998. Gimbel et al. compared those rates to those of England (292 per 100,000) and the 
US (425 per 100,000) during the same time period, noting the overall lower incidence in Denmark.
10
 
 The overall average age at hysterectomy in the US is 46 years old,
3
 but the surgical approach 
varies by age. In 2003, approximately two-thirds of hysterectomies for benign gynecologic conditions 
were performed abdominally, with a mean age of 44.5 years at hysterectomy. Vaginal hysterectomies, 
which account for approximately 20% of hysterectomies, were performed at an average age of 48.2 
years and laparoscopic hysterectomies (12% of hysterectomies) were performed at a younger mean 
age of 43.6 years.
11
 Hysterectomies performed for uterine leiomyomas (fibroids) were more 
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frequently abdominal while those for uterine prolapse were more frequently vaginal;
11
 this coincides 
with the reported mean ages at hysterectomy since younger women are more likely to undergo 
hysterectomy for fibroids or endometriosis and older women are more likely to undergo hysterectomy 
for prolapse or cancer.
5
 Concomitant bilateral salpingo-oophorectomy (BSO) was undertaken in 
roughly half of hysterectomies in the US in the late 1990s, up from 25% in 1965; however, this rate 
varies by age.
1,5
 The American College of Obstetricians and Gynecologists recommended in 1999
12
 
and 2008
13
 that BSO be avoided in premenopausal women because negative outcomes associated 
with premature loss of ovarian function outweigh the potential benefits of avoiding future ovarian 
pathology including ovarian cancer.
14
 Thus, during the years 2000-2004, only 37% of hysterectomies 
among women aged 15-44 years included concomitant BSO versus 78% of hysterectomies among 
women aged 50-54 years.
3,15,16
 
 Hysterectomy rates vary by a number of factors, including geographic region, demographics, 
and reproductive characteristics. Women in the US South undergo hysterectomy at higher rates (5.92 
per 1000 women-years) than women in the US Northeast (3.33 per 1000 women-years).
1,11
 Though 
not all studies have shown different hysterectomy rates among racial/ethnic groups,
17,18
 many have 
reported higher rates and/or higher prevalence of hysterectomy among African American women, 
who more often than not undergo abdominal hysterectomy.
1,17,19-21
 Women undergoing hysterectomy 
are also more likely to have had fewer years of education, lower income, be parous, or have had their 
first birth at an early age.
22-24
 
2.1.2 Indications for hysterectomy 
 Most hysterectomies (90%) are performed for benign gynecologic conditions such as 
fibroids; menstrual disorders such as excessive bleeding; uterine prolapse; and endometriosis
8,11,16,25,26
 
but the reasons differ by race/ethnicity. In an analysis of hospital discharge data from the 2003 
Nationwide Inpatient Sample, representing a 20% stratified sample of US hospitals, the most frequent 
indications for hysterectomy were fibroids (33%), menstrual disorders (21%), uterine prolapse (16%), 
and endometriosis (14%) among white women; among African American women, hysterectomies 
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were predominantly performed to treat fibroids (70%) rather than menstrual disorders (12%), uterine 
prolapse (4%), or endometriosis (6%).
11
 
 Uterine fibroids are very common in women and typically appear during a woman’s 
reproductive years.
27,28
 Although they are often symptomatic, fibroids can cause considerable 
morbidity related to pelvic pain, excessive bleeding, and other symptoms. It has been estimated that 
fibroids cost the US billions of dollars per year
29 
and that worldwide, they account for approximately 
40% of all hysterectomies.
8
 Fibroids are positively associated with age during the reproductive years, 
African American race/ethnicity, earlier menarche, obesity, diabetes, hypertension, and polycystic 
ovarian syndrome.
27,28,30-33
 African American women are also more likely to experience more 
numerous and larger fibroids at earlier ages, which may partially explain why they are more likely to 
undergo hysterectomy than white women.
20,34
 
 The true prevalence of endometriosis, the presence of endometrial tissue outside of the uterus, 
is unknown due to a lack of non-invasive diagnostic tests but is thought to be around 10%.
35-37
 It has 
been estimated from surgical studies that the prevalence of endometriosis among fertile women 
undergoing tubal ligation is 3-6% while it is much higher (30-50%) among women with infertility or 
pelvic pain.
38
 Women with endometriosis typically present with symptoms of dysmenorrhea; chronic 
pelvic pain; infertility; bladder and bowel pressure/discomfort; and dyspareunia.
39,40
 A higher 
prevalence of endometriosis has been associated with earlier age at menarche; shorter menstrual 
cycles; nulliparity; lower body mass index (BMI) levels; alcohol and caffeine use; prior pelvic 
surgery; infertility; and family history of endometriosis
38,39,41,42
 however, the etiology remains 
unclear. 
2.1.3 Role of family history in indications for hysterectomy 
 Women with fibroids who have a family history of fibroids may be more likely than women 
without a family history to present with more severe symptoms, and thus be more likely to undergo 
hysterectomy
43,44
 and at an earlier age.
45
 In fact, twin studies indicate that as many as 50-70% of 
fibroids have a heritable component
44,45
 and another study has shown associations with fumarate 
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hydratase gene mutations, which are seen in rare familial syndromes.
46
 It may be that an apparent 
increase in risk for fibroids among women with a family history could be attributed to women with a 
family history being more likely to inquire about symptoms when consulting with their doctor. 
Similarly, one recent study reported no association between family history of fibroids and a fibroids 
diagnosis when cases were limited to women who reported their family history prior to their own 
diagnosis.
47
 
 Though researchers have suggested that “controlling for family history of uterine leiomyomas 
as a proxy for elevated genetic risk could reduce the racial difference in uterine leiomyoma disease 
outcomes,”43 it is clear that the role of family history in fibroids diagnosis requires additional 
research. Broadly defined, family history is a proxy for both inherited factors and shared family 
environment; it is not simply a proxy for genetic risk. 
 A study of twins in Australia reported that the incidence of endometriosis among 
monozygotic twins was twice the incidence among dizygotic twins;
48
 early studies of family history 
of endometriosis among mothers and sisters have reported up to a 6-fold increase in prevalence.
49
 A 
more recent study reported an increase in risk of endometriosis with family history among first-
degree relatives, though of a lower magnitude than in previous studies (odds ratio (OR) =2.03; 95% 
confidence interval (CI): 0.54, 8.25).
40
 Interestingly, the investigators did not find differences in the 
characteristics of the cases, with or without family history, or their symptoms; earlier reports have 
suggested that the severity of endometriosis is higher among women with a family history.
49
 As with 
fibroids, the role of family history of endometriosis with respect to risk, severity of symptoms, and 
outcome requires additional study. 
2.2 Epithelial ovarian cancer 
2.2.1 Epidemiology of ovarian cancer 
 In the US, ovarian cancer is the leading cause of death among cancers of the female 
reproductive tract and is the fifth leading cause of cancer death among women after lung, breast, 
colorectal and pancreatic cancers. In 2015, there will be an estimated 21,290 new cases of ovarian 
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cancer and 14,180 deaths due to ovarian cancer.
50
 Worldwide, the incidence of and death due to 
ovarian cancer is approximately equal between developed and developing countries.
51
 Ovarian cancer 
is a highly fatal disease, in part because reliable screening methods do not exist and most patients 
present with advanced disease. In the US, the five-year survival rate for all stages of disease is 45%; 
patients with localized disease have a five-year survival rate of 92% but only 19% of ovarian cancers 
are diagnosed at this stage. Patients with regional and distant ovarian cancer have five-year survival 
rates of 72% and 27%, respectively.
50
 
2.2.2 Heterogeneity of epithelial ovarian cancer 
 Ovarian cancer is an etiologic heterogeneous collection of tumors. Sex cord-stromal and germ 
cell tumors are rare, accounting for 5-10% and <5%, respectively, of all ovarian tumors. Sex cord-
stromal tumors arise in the connective tissue holding the ovary together and germ cell tumors 
originate in the cells that are destined to form eggs within the ovaries.
52
 Epithelial ovarian cancer 
(EOC), occurring within the cells of the ovarian surface, accounts for over 90% of all ovarian cancers 
and is the focus of our research. 
 Low malignant potential (LMP), or borderline tumors, and invasive tumors are the two main 
types of EOC even though LMP tumors are not considered to be cancerous. There are several 
histologic subtypes of both LMP tumors and invasive EOC: serous, mucinous, endometrioid, clear 
cell, mixed cell, and undifferentiated. Most LMP tumors are serous (50-60%) or mucinous (30%).
53,54
 
Serous is the most common histologic subtype of invasive EOC, accounting for approximately 50% 
of EOC cases. Endometrioid (~20%), mucinous (~10-12%) and clear cell (~8-10%) are much less 
common.
55
 The mucinous subtype is thought to be over diagnosed due to misclassification of 
metastatic tumors from other sites;
56
 some studies have reported frequencies as low as 3% for 
mucinous invasive EOC in their populations.
55
 
 Serous and mucinous EOC are thought to be very different from one another and may have 
different sets of risk factors. Molecularly, k-ras mutations are generally found in mucinous but not 
serous tumors; the opposite is true for p53 mutations.
57
 Mucinous tumors are thought to be associated 
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with younger age compared to non-mucinous tumors
58,59
 and may be associated with environmental 
exposures such as smoking more so than reproductive exposures such as number of children or oral 
contraceptive (OC) use.
52,59-61
 Likewise, the endometrioid and clear cell subtypes are thought to be 
very different from both serous and mucinous EOC, but are often lumped together, especially since 
both are associated with endometriosis.
53,56,62
 
 Most LMP tumors do not appear to progress to invasive EOC.
53,57,63
 LMP serous and invasive 
serous EOC have some molecular differences: p53 mutations in invasive serous, loss of 
heterozygosity (LOH) on the long arm of the inactivated x chromosome in LMP serous and 
microsatellite instability in LMP serous.
57
 If LMP serous tumors progressed to invasive serous EOC, 
we would expect to see the same kind of molecular profiles in both types of serous EOC.
53
 Mucinous 
EOC appears to be the only histologic subtype to follow a progression model whereby LMP tumors 
progress to invasive tumors.
54,56,57
 The LOH profiles of both LMP and invasive mucinous EOC are 
very similar.
57
 
2.2.3 Ovarian cancer pathogenesis 
 Despite the high mortality from ovarian cancer and the burden of disease, the etiology is not 
clearly understood. Though the mechanisms underlying them are not fully described, reproductive 
factors such as parity, OC use, breast-feeding, endometriosis, and tubal ligation have been established 
as factors associated with EOC risk.
64
 Cases of ovarian cancer are primarily sporadic; however, 5-
10% are familial, primarily due to germline mutations in the BRCA1 and BRCA2 tumor suppressor 
genes.
65
 
 In 1971, Fathalla postulated that “incessant ovulation” might play a role in the development 
of ovarian neoplasms due to recurrent repair and exposure of the epithelium of the ruptured follicles 
to estrogen-rich follicular fluid.
66
 The gonadotropin hypothesis suggests that high levels of pituitary 
gonadotropins, within normal cycles, increase cancer risk by stimulating the ovarian surface 
epithelium, a proliferative process that may propagate mutations and promote carcinogenesis.
67
 Other 
etiologic hypotheses include: inflammatory response in the ovarian epithelium due to retrograde 
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transportation of contaminants or endogenous carcinogens,
68,69
 a pregnancy-dependent clearance of 
malignant cells from the ovaries,
70
 and hormonal imbalances resulting in excess androgen and 
deficiency in progesterone.
71
 
2.3 Hysterectomy and ovarian cancer 
2.3.1 Association between hysterectomy and epithelial ovarian cancer 
 In general, the literature suggests that hysterectomy is protective against EOC. In a large, 
pooled case-control study of invasive EOC
72
 hysterectomy was significantly protective for the 
hospital-based case-control studies (OR=0.66, 95% CI: 0.50, 0.86); the result was slightly attenuated 
for the population-based case-control studies (OR=0.88, 95% CI: 0.72, 1.1). Harris et al.
73
 also 
reported a decreased risk of LMP EOC (OR=0.87, 95% CI: 0.58, 1.3). Similar estimates have been 
reported in other case-control studies
58,61,74-81
 and in cohort studies.
82-85
 
 Several studies have looked at the effect of hysterectomy alone and hysterectomy with 
unilateral oophorectomy on EOC risk. One study reported that a non-significant decreased risk of 
EOC was limited to women who had hysterectomy without unilateral oophorectomy.
86
 Four studies 
report no substantial differences in the association with EOC between the hysterectomy alone and 
hysterectomy with unilateral oophorectomy groups; 
75,85,87,88
 however, these studies included very 
small numbers of participants exposed to hysterectomy. 
 Two studies reported an increased risk of LMP mucinous tumors. Jordan et al.
60
 reported that 
women with hysterectomy were twice as likely to have an LMP mucinous tumor than women without 
hysterectomy (OR=2.0, 95% CI: 1.3, 3.2); they found no association between hysterectomy and 
invasive mucinous tumors. Another case-control study also found an increased risk of LMP mucinous 
tumors among women with hysterectomy (OR=1.18, 95% CI: 0.53, 2.60).
61
 Other studies found no 
differences in association among the different histologic subgroups.
58,61,80
 
 Only two studies statistically evaluated effect measure modification by endometriosis or 
parity. In a pooled case-control study, hysterectomy was protective against EOC among women with 
endometriosis (OR=0.69, 95% CI: 0.38, 1.24) but not women without endometriosis (OR=1.02, 95% 
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CI: 0.68, 1.23, p for interaction=0.24).
89
 It is important to note that these findings were for EOC 
overall, rather than for the endometrioid or clear cell subtypes alone. The endometrioid and clear cell 
subtypes of invasive EOC are both associated with endometriosis
56
 so there is the possibility that the 
effect of hysterectomy on EOC risk among women with endometriosis might be different according 
to the different histologic subtypes. Hysterectomy was protective against EOC for both nulliparous 
women (OR=0.29, 95% CI: 0.10, 0.81) and parous women (OR=0.56, 95% CI: 0.39, 0.80, p for 
interaction=0.46) in another study.
81
 
2.3.2 Timing of hysterectomy and epithelial ovarian cancer 
A “healthy screenee” effect may explain the reported inverse association between 
hysterectomy and EOC. Some women who are undergoing surgery for hysterectomy have their 
ovaries visualized and checked for abnormalities during surgery, giving the doctor a chance to detect 
ovarian cancer or possible pre-cursors.
90
 If this were the case, only hysterectomies performed close in 
time to the diagnosis of EOC would show a protective effect. One study showed support for this 
“healthy screenee” hypothesis. Weiss and Harlow90 report protective odds ratios for hysterectomies 
less than five years prior to diagnosis or interview. However, hysterectomy appeared to be deleterious 
at six to ten years (OR=1.4, 95% CI: 0.83, 2.4) and at greater than ten years (OR=1.6, 95% CI: 1.1, 
2.2). 
The inconsistencies in the literature on this topic are likely due to insufficient power to detect 
associations due to very small sample size; however, most studies do not support the hypothesis.
72,76-
78,81,83,86,88
 One study reported that risk of EOC decreased as time since surgery increased and that the 
decrease in risk was highest 25 years prior to diagnosis.
77
 Another study reported a similar decrease in 
risk over time (Risk Ratio (RR)=0.95, 95% CI: 0.91, 1.00 for each year from surgery).
88
 Though 
Risch et al. reported a very small decrease in risk per year since hysterectomy (RR=0.996, 95% CI: 
0.97, 1.03), the protective effect of hysterectomy remained after 20 years.
81
 Whittemore et al. also 
reported a sustained protective effect, with even a decrease in risk over time for women in the 
population-based case-control studies that were pooled (RR=0.99, 95% CI: 0.71, 1.40 for 2-9 years 
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since hysterectomy; RR=0.86, 95% CI: 0.63, 1.20 for 10-19 years; and RR=0.79, 95% CI: 0.53, 1.20 
for 20+ years).
72
 Finally, in a large case-control study, women who reported hysterectomy more than 
15 years prior to diagnosis/interview were at the lowest risk of invasive EOC (OR=0.6, 95% CI: 0.4, 
0.9).
76
 
2.3.3 Age at hysterectomy and epithelial ovarian cancer 
 Whittemore et al.
91
 asserted that hysterectomy might impair ovarian function by comprising 
blood flow to the ovaries, thereby resulting in anovulation. If this were the case, hysterectomy during 
a woman’s reproductive years would confer more protection than hysterectomy after menopause. 
Though the age at hysterectomy cut-point varied among the analyses (e.g., 40, 45, 55), most 
published reports suggest no difference between hysterectomy performed during the reproductive 
years and the post-menopausal years.
76,78,81,82,86,88
 There were, however, two reports that lend support 
to the hypothesis that hysterectomy in the reproductive years offers more protection against ovarian 
cancer. In a historical cohort study in Canada, there were significantly fewer ovarian cancers 
observed among women who had had a hysterectomy between the ages of 25 and 44 
(Observed/Expected=0.55, p<0.001).
83
 Additionally, Whittemore and colleagues reported that women 
who had hysterectomy before age 40 were 42% less likely to have EOC (OR=0.58, 95% CI: 0.40, 
0.86) than women who had not had a hysterectomy. Women who had hysterectomy after the age of 
40 were only 27% less likely to have EOC than women who had not had a hysterectomy (OR=0.73, 
95% CI: 0.51, 1.00). These pooled results were from six hospital-based case-control studies; the 
pooled results from six population-based case-control studies were attenuated and were more similar 
across age at hysterectomy strata.
72
 
2.4 Conclusions 
 Currently, there are no known multivariate prediction models for premenopausal 
hysterectomy with ovarian conservation, which account for a large proportion of all hysterectomies 
performed. While we generally know that women with uterine fibroids, endometriosis, and other 
menstrual-related conditions choose to undergo hysterectomy for treatment of their common, benign 
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gynecologic condition(s), we need to have a better understanding of other factors that may be related 
to their decision. Additional traits, including family history of common, benign gynecologic 
conditions, may help identify women for clinical monitoring, and potentially less invasive treatment. 
Additionally, information about women who have hysterectomies may inform imputation models for 
missing hysterectomy status and future studies with respect to enrolling appropriate participants for 
studies of hysterectomies. 
 Related to the need for a better understanding of premenopausal hysterectomy is a need for 
more careful analyses of the association between hysterectomy and ovarian cancer. Both the exposure 
(hysterectomy) and outcome (EOC) have not been identified in a standardized way throughout the 
literature. While some studies specify EOC, and go further to distinguish between invasive and LMP 
tumors, other studies simply defined their outcome as ovarian cancer. Non-epithelial ovarian cancers 
are associated with different risk factors and should be analyzed separately. Additionally, while some 
studies analyze invasive and LMP tumors separately (or combine them after checking that the 
exclusion of LMP tumors didn’t appreciably change the results), other studies simply combine the 
two types of tumors. Since there is some evidence that hysterectomy may have a different association 
with LMP EOC 
60,61
, than with invasive EOC, it is important to describe any differences between 
them. 
 The hysterectomy and ovarian cancer literature is outdated; the largest sample analyzed
72
 is 
more than 25 years old and only one study 
60
 has published data on women from beyond the year 
1999. Because hysterectomy rates have been changing in the past few decades, as have rates of 
concomitant oophorectomy, it is important to update the literature with current studies and larger 
sample sizes. 
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CHAPTER 3. METHODS 
3.1 Association between hysterectomy and epithelial ovarian cancer 
3.1.1 Specific aims 
The specific aims of the study for the association between hysterectomy and epithelial ovarian cancer 
are as follows: 
1) Specific aim 1: Determine the association between hysterectomy and epithelial ovarian 
cancer. 
2) Specific aim 2: Determine the association between timing of hysterectomy (with regard to the 
time at diagnosis among cases and time at interview/reference point among controls) and 
epithelial ovarian cancer. 
3) Specific aim 3: Determine the association between age at hysterectomy and epithelial ovarian 
cancer. 
3.1.2 Overview of methods 
 We will conduct a pooled analysis of epithelial (EOC) cases and controls from 15 studies in 
the Ovarian Cancer Association Consortium (OCAC) to evaluate the association between 
hysterectomy, time since hysterectomy, and age at hysterectomy and subtypes of EOC. Study-specific 
ORs will be calculated by conditional logistic regression conditioned on age and race/ethnicity and 
adjusted for by a minimally sufficient adjustment set (MSAS) of covariates identified by an 
evaluation of a directed acyclic graph (DAG) representing the relationships among the exposure of 
interest (hysterectomy), the outcome (EOC), known and suspected risk factors for EOC, and factors 
associated with hysterectomy. The study-specific estimates will be pooled using random-effects 
models; 95% prediction intervals (PI) will be calculated when between-study variance is greater than 
zero. 
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3.1.3 Study populations and data sources 
 The OCAC was formed to create an opportunity for researchers to evaluate genetic 
associations with ovarian cancer with increased power due to larger sample size. While a major aim 
of the OCAC is to follow up on promising genetic associations while addressing the issues of 
multiple comparisons and false discoveries that are inherent to studies using high-throughput 
genotyping technologies,
92-99
 investigators are keen to take advantage of the rich epidemiologic data 
that is available. To date, there have been over 60 peer-reviewed manuscripts published that highlight 
the work of the OCAC to identify and validate genetic associations with EOC
100-104
 and to evaluate 
known and suspected risk factors for subtypes of EOC.
62,105-108
 
 Fifteen OCAC case-control studies agreed to participate in our proposed analyses of 
hysterectomy and EOC. One study is from Australia (AUS); one is from the UK (UKO); four are 
from Europe (GER, MAL, NTH, POL); and nine are from the United States (CON, DOV, HAW, 
HOP, NCO, NEC, STA, UCI, USC). 
 EOC cases were identified predominantly through cancer registries and hospital tumor or 
pathology boards; these cases are considered to be population-based. All but two of the studies (NTH, 
UKO) contributed both low malignant potential (LMP) and invasive EOC tumors to the OCAC 
database. Two of the studies (DOV and USC) received pathology information from their respective 
Surveillance, Epidemiology, and End Results cancer registries. A majority of the study sites centrally 
reviewed pathology information from patients' pathology reports and a subset of studies confirmed 
pathology, tumor behavior, and histology by examination of histopathological slides (CON, HAW, 
MAL, NCO, STA, and UCI). All but three studies (NTH, UCI, UKO) enrolled incident cases of 
ovarian cancer and collected epidemiologic data within one year of the ovarian cancer diagnosis, on 
average. 
 Controls were predominantly recruited through random digit dialing, population rosters, and 
neighborhoods; these controls are generally considered to be population-based. Controls from the 
NTH study were recruited from the Nijmegen Biomedical Study, a population-based survey based on 
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an age-stratified random sample of the population of Nijmegen. Controls from the UKO study were 
postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer 
Screening. All controls had to be at risk for ovarian cancer at the time of enrollment and therefore, 
had to have at least one intact ovary. Women reporting bilateral salpingo-oophorectomy (BSO) were 
not eligible for any of the studies. If a woman was unsure of her ovarian status (i.e., whether she had 
previously had a BSO), she was excluded from the following studies: CON, DOV, HAW, NEC, STA, 
and USC. 
 Participants from each of the studies completed questionnaires that ascertained demographic 
information on the known and suspected risk factors for ovarian cancer including: family history of 
breast and/or ovarian cancer; menstrual and reproductive histories; use of exogenous hormones such 
as oral contraceptive (OC) and hormone replacement therapy (HRT); medical and surgical histories; 
height and weight at various times in life; smoking history; and diet and medication use patterns. Not 
all studies collected information on the covariates of interest in this study: body mass index (BMI) in 
early adulthood and/or endometriosis were not collected by the NTH, POL, and STA studies. 
3.1.4 Statistical methods 
3.1.4.1 Exposures 
 The primary exposure of interest will be defined as hysterectomy that occurred more than 2 
years prior to diagnosis (cases) or interview/reference data (controls). Women reporting hysterectomy 
within two years of diagnosis will be considered "unexposed" to avoid including cases whose 
hysterectomies were related to their sub-clinical ovarian cancer in the exposed group. Additionally, 
since we will only have ages at diagnosis and hysterectomy, we want to avoid including cases in the 
exposed group whose hysterectomies were part of their surgery to remove ovarian tumors. In 
preliminary analyses, the percentage of hysterectomies occurring with 2 years of diagnosis or 
interview was less than 10% for controls from all studies and for cases from most studies. Eleven 
percent of cases from the CON study, 41% of cases from the UKO study, and a majority of cases 
from the NTH and POL studies (54% and 71%, respectively) occurred within two years of diagnosis 
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and will be considered unexposed. To evaluate the association between age at hysterectomy and 
EOC, and because a majority of hysterectomies will have occurred prior to menopause or before age 
50 (a common proxy for age at menopause), we will dichotomize the hysterectomy groups (<40 and 
≥40 years of age). To evaluate the association between time since hysterectomy and EOC, we will 
group the hysterectomies into three groups: 2- <15 years, 15- <30 years, and ≥30 years). 
3.1.4.2 Outcomes 
 To facilitate comparisons with the published literature, we will analyze all invasive EOC 
cases combined and all LMP tumors combined. However, because invasive EOC is a heterogeneous 
disease, we will define the case groups by tumor behavior and histology as follows: LMP serous, 
invasive serous EOC, invasive endometrioid EOC, and invasive clear cell EOC. For mucinous 
tumors, we will evaluate LMP mucinous tumors and invasive mucinous EOC cases combined and 
separately. Because research has suggested that low-grade invasive serous EOC more closely 
resembles LMP serous tumors, and because low- and high-grade invasive serous EOC may arise via 
different pathways, we will also evaluate them separately.
109,110
 
3.1.4.3 Control of confounding 
 All study-specific estimates will be adjusted for age (<40; 40- <45; 45- <50; 50- <55; 55- 
<60; 60- <65; 65- <70; 70- <75; and ≥75) and race/ethnicity (non-Hispanic white, Hispanic white, 
black, Asian, and other). All study-specific estimates for the associations between the different 
hysterectomy exposures and the different LMP and invasive EOC outcomes will also be adjusted for 
a set of covariates, identified a priori, by careful consideration of causal diagrams. We constructed 
DAGs
111,112
 to identify a MSAS for each of the different hysterectomy-outcome pairings using the 
DAG program v0.20 (http://epi.dife.de/dag/).
113
 Because the outcome groups share many risk factors, 
the MSAS are similar. For the overall LMP, LMP serous, overall invasive and invasive serous 
models, the MSAS includes: BMI in early adulthood (<18.5; 18.5- <25; 25- <30; and ≥30); number of 
full-term births (0; 1; 2; 3; and ≥4); duration of OC use (0; <24, 24- <60; 60- <120; and ≥120 
months); tubal ligation; and history of breast or ovarian cancer in the mother. The MSAS for the 
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invasive endometrioid and clear cell ovarian cancer models additionally includes self-reported 
endometriosis. The MSAS for the mucinous ovarian cancer models includes only age and race. 
Variables that were included in the DAGs but not identified as part of the MSAS were: age at 
menarche; breastfeeding; estrogen replacement therapy; combination hormone replacement therapy; 
unilateral oophorectomy; smoking; uterine leiomyomata; lifetime number of ovulatory cycles; 
premature ovarian failure; age at menopause; pelvic pain; abnormal uterine bleeding; and menopausal 
symptoms. 
3.1.4.4 Study-specific estimates of association 
 We will estimate study-specific odds ratios (OR) and 95% confidence intervals (CI) for the 
associations between the different hysterectomy exposures and the different EOC outcomes using 
conditional logistic regression; the design variables of age and race/ethnicity will define the 
conditioning sets. We will produce both unadjusted estimates and estimates adjusted for the MSAS 
identified by the DAGs. 
3.1.4.5 Pooling of data 
 We will obtain estimates of the mean and variance of random-effects distributions using the 
restricted maximum likelihood method of DerSimonian and Laird
114,115
 in meta-regression models 
without regressors (i.e., intercept-only) to get estimates of the mean and variance of random effects 
distributions. A random-effects model produces estimated values of the mean (𝜇) and variance (𝜏2) of 
a presumptively normal distribution of “true” values: in this case, a distribution of log odds ratios 
across different populations. The antilog of the distribution’s estimated mean, ?̂?, may be considered a 
point estimate of the average OR, which is reported along with a 95% CI to reflect the role of 
sampling error. We will describe the estimated variance (spread) of the random-effects distribution by 
computing the opposite effects proportion (OEP) and 95% PI. The OEP is our name for the area 
under the curve on the opposite side of the null value from the estimated mean
116
. For instance, if 
?̂? > 0, the estimate of the average odds ratio is greater than 1, and the OEP estimates the proportion 
of populations in which the odds ratios are below 1. The 95% PI, which is calculated (on the log OR 
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scale) as ?̂?  ±  𝑡𝑘−2 √?̂?2 + 𝑆?̂?(?̂?)2 , where 𝑘 is the number of studies in the meta-analysis, 𝑡𝑘−2 is the 
2.5th percentile of the 𝑡 distribution with 𝑘 − 2 degrees of freedom, and 𝑆?̂?(?̂?)2 is the estimated 
standard error of the sampling distribution for ?̂?117-119. Technically, in hypothetically endless 
repetitions of the entire ensemble of 𝑘 studies, 95% of the 95% PIs cover the “true” OR to be 
estimated in the “next” study (i.e., study number 𝑘 + 1). As a practical matter, the 95% PI is 
attractive because its width is determined not only by the estimated spread of the random-effects 
distribution, ?̂?2, but by the estimated degree of random error, in the form of 𝑆𝐸(?̂?)2. When ?̂?2 > 0, 
the 95% PI for the next odds ratio is wider than the 95% CI for the average OR. When ?̂?2 = 0, the 
random-effects model reduces to a fixed-effect model and the two intervals become identical. 
3.1.4.6 Heterogeneity of results 
 We will evaluate a list of study characteristics related to study validity and general 
characteristics of time and place, one at a time in a series of meta-regressions, to identify potential 
sources of heterogeneity of results. Regarding study validity, we will consider: case type (population-
based/hospital- or clinic-based); prevalence of cases defined by mean time between diagnosis and 
interview (≤1 year/>1 year); control sampling (concurrent with cases/after cases were enrolled); and 
enrollment of controls unsure of oophorectomy status (explicitly not enrolled because of 
indeterminate eligibility/included). We will evaluate the following characteristics related to time and 
place: location (United States (US)/non-US); median year of diagnosis (≤2000/2000- ); age-
standardized prevalence of hysterectomy among controls (<15%/≥15%) as a surrogate for how 
common hysterectomy is in the source populations; and median year hysterectomies were performed 
among controls (<1980/1980- ). To address multiple testing in our evaluation of these study 
characteristics, we will perform Monte Carlo permutation tests as described by Higgins and 
Thompson
120
 and, a priori, use a multiplicity adjusted alpha of 0.05 for identifying study 
characteristics that explain heterogeneity. 
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3.2 Prediction of premenopausal hysterectomy 
3.2.1 Specific aims 
The specific aims of the prediction of premenopausal hysterectomy study are as follows: 
1) Specific aim 1: Develop and internally validate a predictive model for hysterectomy with the 
intention of ovarian conservation among premenopausal women. 
2) Specific aim 2: Evaluate the contribution (i.e., incremental value) of family history of 
common, benign gynecologic conditions among mothers and sisters to the predictive model 
for hysterectomy with intention of ovarian conservation among premenopausal women. 
3.2.2 Overview of methods 
 We will use unconditional logistic regression to predict hysterectomy with the intention of 
ovarian conservation among pre-menopausal women enrolled in Prospective Research on Ovarian 
Function (PROOF): A Study of Hormonal Changes in Premenopausal Women. By review of the 
scientific literature, we have selected, a priori, the following variables to be included in the model: 
age; self-identified race; marital status; education level; duration of OC, number of full-term 
pregnancies; tubal ligation; uterine leiomyoma (fibroids); endometriosis; ovarian cysts; previous 
myomectomy; smoking status; and BMI. The model’s discriminatory power (i.e., ability to classify 
correctly) will be evaluated using the concordance statistic (i.e., c statistic), which is equivalent to the 
receiver operating characteristic (ROC) area under the curve (AUC) in a logistic regression model. 
Model calibration (i.e., correspondence between the model-predicted probabilities and the observed 
probabilities) will be evaluated with a goodness-of-fit test and visual inspection of the observed 
versus predicted probabilities plots. Internal validation of the model will be performed by correcting 
the AUC for optimism/overfit by using bootstrap methods. 
 We will evaluate the incremental value of adding information regarding family history of 
common, benign gynecologic conditions in the mother and/or sister(s) to the prediction model by 
comparing the AUC from the model with that dichotomous variable to the AUC from the original 
model described above. 
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3.2.3 Study populations and data sources 
 PROOF: A Study of Hormonal Changes in Premenopausal Women was a cohort study of 
premenopausal women conducted in Durham, North Carolina from April 1, 2004 through December 
2007.
34,121-123
 Women between the ages of 30 and 47 years undergoing hysterectomy at Duke 
University Medical Center or Durham Regional Hospital, both part of the Duke University Health 
System and located in Durham, North Carolina, were enrolled. Women with intact uteri attending 
general gynecology practices in Durham, North Carolina were frequency matched to the women 
undergoing hysterectomy on age and race. The aims of the original study were to prospectively 
determine whether women undergoing hysterectomy were more likely to experience ovarian failure 
during the four years after hysterectomy than the women with intact uteri and to identify medical, 
reproductive, and lifestyle characteristics that may be associated with earlier ovarian failure.
121
 This 
analysis will only include baseline data for the women who underwent hysterectomy, hereafter 
identified as cases, and the women with intact uteri, hereafter identified as controls. 
 Cases were women, aged 30 to 47 years, who were scheduled to undergo hysterectomy for 
benign gynecologic conditions. Prior to their scheduled hysterectomy, potentially eligible women 
received a letter from their physician describing the study and alerting them that study personnel 
would be contacting them to request their participation. In addition to being aged 30 to 47 years and 
not pregnant, women had to be premenopausal as evidenced by at least one menstrual period in the 
previous 3 months, had to have at least one intact ovary prior to and following the hysterectomy, had 
to have no personal history of cancer (except nonmelanoma skin cancer), and had to be able to 
complete the interview in English. Premenopausal status was confirmed by a pre-operative blood 
level of follicle-stimulating hormone (FSH) less than 40 international units per liter (IU/L). Seventy-
seven percent of the women identified as scheduled to undergo a hysterectomy remained eligible for 
the study and 72% of those women completed the baseline interview and provided blood samples. Of 
the 501 potential cases who completed the baseline interview, 4 were excluded because they did not 
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undergo hysterectomy, 6 were excluded due to pre-operative FSH levels ≥ 40 IU/L, and 41 were 
excluded because they underwent a bilateral oophorectomy at the time of their hysterectomy. An 
additional 7 women from the control group were also included as cases because they ended up 
undergoing hysterectomy within one year after enrollment. Though 47 cases did not complete follow 
up in the prospective aspect of the original study, they are included in the proposed analysis of 
baseline data; the final number of cases in this baseline analysis will be 457. 
 Controls were recruited using brochures and advertisements that were placed in gynecology 
and family medicine clinics/practices in the Duke University Health System in Durham, North 
Carolina. Controls were subject to the same eligibility criteria as the cases. Of the 523 potential 
controls who completed the baseline interview, 15 were excluded due to pre-operative FSH levels ≥ 
40 IU/L and 2 were excluded due to no blood sample (i.e., inability to confirm premenopausal status 
by FSH level). Though 32 controls did not complete follow up in the prospective aspect of the 
original study, they are included in the proposed analysis of baseline data; the final number of 
controls in this baseline analysis will be 506. The controls who remained eligible for the study after 
the exclusions described above had a higher educational level and were less likely to smoke than the 
controls who were excluded but were similar otherwise. 
 Participants enrolled in the study completed a baseline interview visit during which they 
signed a consent form, completed an extensive questionnaire that was administered by a study 
interviewer, provided a blood specimen, and had anthropometric measurements taken. For the cases, 
the baseline interview occurred prior to their hysterectomies, most at the time of their pre-operative 
visits. The questionnaire ascertained information on the following: demographics; menstrual cycle 
history; reproductive history; medical and gynecologic condition history; family history; and lifestyle 
characteristics related to alcohol, smoking, diet, and physical activity. 
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3.2.4 Statistical methods 
3.2.4.1 Specific aim 1 
3.2.4.1.1 Predictors 
 Steyerberg et al.
124
 caution against basing the structure of prediction models solely on the 
data under study, especially when the dataset is small, and suggest that previously published or 
clinically practical parameterizations of variables are preferred over classifications that best fit the 
data. Based on a review of the scientific literature, we selected the following predictors, a priori, for 
inclusion in the prediction model for hysterectomy with intent of ovarian conservation among 
premenopausal women: age; self-identified race; marital status; education level; duration of OC use, 
number of full-term pregnancies; tubal ligation; fibroids; endometriosis; ovarian cysts, previous 
myomectomy; smoking status; and BMI. 
 To avoid overfitting the model, the parameterizations of the predictors have also been 
prespecified and are described in detail in Table 1. Briefly, dichotomous categorical variables (i.e., 
tubal ligation; fibroids; endometriosis; ovarian cysts; and previous myomectomy) will remain as such 
in the model. Nominal categorical variables (i.e., race; marital status; education level; and smoking 
status) will remain as such in the model with similar categories being grouped together to decrease 
the degrees of freedom being used in the model. Age will remain a linear predictor in the model. It 
has been reported that dichotomization of predictors results in a loss of discriminative ability
124,125
 and 
as such, the remaining continuous variables (i.e., duration of OC use, number of full-term 
pregnancies, and BMI) will be included as more flexible restricted cubic splines with 3 or 4 knots.
126
 
Tests for interaction generally require larger sample sizes to provide adequate statistical power. 
Additionally, there are no known important interactions to consider a priori, based on review of the 
literature. As such, we will only include main effects in the proposed prediction model. 
 Overall, we propose the inclusion of 13 predictors in the prediction model, with 21 degrees of 
freedom. With 457 women having undergone hysterectomy, the number of events per variable (EPV) 
is 35 and the number of events per degree of freedom is 21. In simulation studies, no major problems 
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occurred when the EPV was greater than or equal to 10.
127
 Subsequent investigators have questioned 
that guideline, especially in the presence of high regression coefficients and strong correlations 
between predictors,
128
 while others argue that there are circumstances in which model performance is 
acceptable even with less than 10 EPV.
129
 
3.2.4.1.2 Missing data 
 In complete case analyses, any participant missing data on at least one predictor included in a 
regression model would be dropped from analyses, resulting in an inefficient analysis and potentially 
biased estimates, depending on the type of missing data. Using an indicator for missing data is also 
not recommended.
130,131
 First, we will assess the frequency of missing data for each of the variables 
included in the prediction models by case/control status. If the extent of missingness in the variables 
is low overall (i.e., <5%), and does not appear to be differential with respect to outcome, we will 
proceed with a complete case analysis. Because we anticipate a moderate percentage of participants to 
be missing data on family history of common, benign gynecologic conditions, we will review the 
distributions of the variables in the prediction model by data status (i.e., non-missing, missing) for 
family history. Additionally, we will perform a sensitivity analysis to evaluate the scope of impact the 
participants missing data might confer on the model's performance by fitting the logistic regression 
for the full model an additional two times: firstly, we will recode the missing family history 
observations as "no" family history and secondly, we will recode the observations as "yes" family 
history. 
3.2.4.1.3 Model specification and estimation 
 I will use unconditional logistic regression to predict hysterectomy with the intention of 
ovarian conservation coded as yes (cases) or no (controls), among pre-menopausal women enrolled in 
the PROOF Study; coefficients will be estimated with maximum likelihood methods. The model will 
include all predictors as described above and in Table 1, with the exception of the dichotomous 
variable for family history of common benign gynecologic conditions in the mother or sister(s), which 
is reserved for specific aim 2. 
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 Though the practice is common, several studies have concluded that stepwise selection 
methods for inclusion (or exclusion) of predictors in a model are deficient, often resulting in 
overestimation of regression coefficients and loss of predictive power.
124,132,133
 In a simulation study, 
Steyerberg et al.
124
 evaluated a model that contained 8 true and 9 noise predictors that were randomly 
associated with the outcome. Compared to a model containing only the true predictors (AUC=0.802), 
the model with noise predictors was only marginally less discriminative (AUC=0.785). When 
stepwise selection methods were applied to the full model of 17 predictors (α=0.05), all 9 noise 
predictors were eliminated from the model, but so were 5 of the 8 true predictors, resulting in an AUC 
of 0.749. Because of these reports, and the relatively small size of the PROOF dataset, we will not 
apply any selection methods to the prediction model in order to identify a final set of statistically 
significant predictors. 
3.2.4.1.4 Model performance 
 The prediction model’s performance will be evaluated by both discrimination and 
calibration.
134,135
 Discrimination, the ability of the model to correctly classify women with and 
without hysterectomy, is most commonly assessed using the concordance statistic (c statistic), a rank-
order statistic for predictions against actual outcomes. For a binary outcome, the c statistic is 
equivalent to the AUC; the true positive rate (i.e., sensitivity) is plotted on the y-axis against the false 
positive rate (i.e., 1-specificity) on the x-axis. It is interpreted as the probability that a patient with a 
higher predicted probability has the outcome when two patients, one with and one without the 
outcome, are considered. We will present both the ROC curve and the AUC value (i.e., c statistic). 
 Though calibration is often very good in model development and critical in external 
validation,
133
 we will evaluate it for the prediction models without and with family history of 
common, benign gynecologic conditions . Calibration is the agreement between the observed and 
predicted outcomes and will be assessed with the Hosmer-Lemeshow Goodness of Fit (GOF) test, a 
chi-squared test based on the grouping of similar participants into n strata (often 10) on the basis of 
their probabilities. These strata will be visualized by plotting the observed proportion of cases on the 
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y-axis against the predicted probability of hysterectomy on the x-axis. We will also estimate the 
intercept and slope of the calibration line in a logistic regression by regressing the observed outcome 
on the predicted probabilities; perfect calibration, whereby the observed distributions of outcomes and 
predicted probabilities are in complete agreement, is indicated by an intercept of 0 and a slope of 1.
136
 
3.2.4.1.5 Model validation 
 Internal validation, the validity of the model in the underlying population that the data came 
from, may address issues of stability in predictor selection (which we will not employ) and quality of 
the predictions. The apparent performance of a prediction model is always better in the 
training/development set than it is in a validation set, even when the two datasets come from the same 
population; the magnitude of this “optimism” can be used to correct performance metrics such as the 
AUC. 
 Internal validation is commonly performed using a split-sample approach: a (usually random) 
percentage of the study population is included in the training/development stage of prediction and the 
remaining percentage of the study population is used for validation of the model. In simulation 
studies, this method resulted in underestimation of the model’s performance, unstable estimates, and a 
high root mean squared error (RMSE); large sample sizes are also required to make this method 
reasonable. In cross-validation, development occurs in a percentage of the population, validation 
occurs in the remaining percentage, and vice versa; this procedure is repeated numerous times and the 
average is taken as an estimate of performance. In simulation studies, this method was preferred over 
split-sample validation but it did not accurately estimate all of the performance measures. 
Bootstrapping methods performed similarly to cross-validation methods in the simulation studies, 
resulting in stable and nearly unbiased estimates of performance; bootstrapping also resulted in the 
lowest RSME values across methods.
137
 
 Investigators reported that 50 to 100 bootstrap samples with replacement were sufficient in 
their simulations but advised a higher number in practice;
137
 we will use 200 bootstrap samples to 
internally validate the prediction model for hysterectomy with intention of ovarian conservation 
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among premenopausal women in each of the bootstrap datasets. The training/development sample 
will include 100% of the participants outlined above from the PROOF study. The bootstrap samples 
will also be drawn from 100% of the participants, resulting in bootstrap samples the same size as the 
training/development set; on average 63.2% of the participants will be included in at least one 
bootstrap sample.
138
 The bootstrap is used to estimate optimism, the decrease in performance between 
the bootstrap sample and performance in the original sample. The optimism-corrected performance is 
then calculated by subtracting the optimism from the apparent performance of the model in the 
original training/development sample.
134
 The observed optimism will be used to correct the AUC. An 
independent study population has not been identified for this prediction model and thus, no external 
validation will be carried out. It has been suggested that even internal validation with bootstrapping 
methods is not sufficient in small datasets
139
 so external validation will need to eventually be carried 
out if this model is to be considered for clinical practice or other settings. 
3.2.4.2 Specific aim 2 
 All of the methods described above will be repeated for a prediction model that includes one 
additional predictor variable with 1 degree of freedom. The variable regarding family history of 
common, benign gynecologic conditions in the biological mother or sisters will be a dichotomous 
summary variable (yes/no) derived from multiple yes/no interview questions regarding endometriosis, 
fibroids, and ovarian cysts in first-degree relatives (the biological mother or sisters). Daughters are 
not considered because the premenopausal women included in this study will, on average, not have 
daughters old enough to have had the opportunity to be diagnosed with these common, benign 
gynecologic conditions. 
 Whether the addition of family history information substantially improves prediction will be 
tested by evaluating whether the difference between the two models’ AUC equals zero;140 the change 
in the AUC will likely depend on the strength of the model developed in Aim 1.
141
 Additionally, we 
will present a reclassification table,
142
 stratified by observed outcome
143
 which will show how many 
subjects were reclassified by adding the family history variable to the prediction model. To further 
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describe the reclassification, we will calculate the percent of patients reclassified and the percent of 
reclassified patients that were reclassified correctly
144
 as well as the Net Reclassification 
Improvement (NRI).
143,145
 The NRI is similar to the percent of patients reclassified, but it takes into 
account movements in the correct direction. In other words, the NRI reflects the movement of cases 
upward and the movement of controls downward, calculated in the following way: 
NRI = [Pr(up|cases) – Pr(down|cases)] – [Pr(up|controls) – Pr(down|controls)] 
Alternatively, it can be rearranged to be the sum of the relative improvement for cases and relative 
improvement for controls. It has been reported that the NRI depends mainly on the effect size of the 
added predictor rather than the strength of the baseline model.
141
 Though this newly developed 
prediction model (as well as the model developed in Aim 1) is not meant to be used for clinical 
decision making, the measures by which we evaluate reclassification may provide insight into future 
models that are intended for clinical use; moving from a prediction model to a prediction rule will 
require external validation in independent studies.
146
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Table 1. Variables included in the prediction models for hysterectomy with the intention of ovarian 
conservation among pre-menopausal women in the Prospective Research on Ovarian Function 
(PROOF) Study 
Predictor 
Self-Report Options / Related 
Questions from Interview 
Parameterization in Prediction 
Models 
Degree(s) 
of Freedom 
Age Age in years Linear 1 
Race 
Nominal categorical: white; 
black/African-American; American 
Indian/Eskimo; Asian/Pacific 
Islander; other 
Nominal categorical: white; 
black/African-American; other 
2 
Marital status 
Nominal categorical: single, never 
married; married; living with 
significant other; divorced/separated; 
widowed 
Nominal categorical: single, 
never married; married/living 
with significant other; 
divorced/separated/widowed 
2 
Education level 
Nominal categorical: 8
th
 grade or less; 
9
th
 to 11
th
 grade; high school 
grad/GED; post high school trade or 
tech school; 1-3 years college; 
college grad; graduate/professional 
school 
Nominal categorical: high school 
graduate or lower; some college 
or post-high school schooling; 
college graduate or higher 
2 
Duration of OC 
use 
Continuous time in years based on 
number of years and months reported 
for total OC use 
Restricted cubic spline with 4 
knots at 1 year; 3 years; 5 years; 
and 10 years 
3 
Number of full-
term 
pregnancies 
Count variable for number of full-
term pregnancies 
Restricted cubic spline with 3 
knots at 1, 2, and 3 pregnancies 
2 
Tubal ligation Dichotomous categorical: yes, no Dichotomous categorical: yes, no 1 
Uterine 
leiomyomas 
(Fibroids) 
Dichotomous categorical: yes, no Dichotomous categorical: yes, no 1 
Endometriosis Dichotomous categorical: yes, no Dichotomous categorical: yes, no 1 
Ovarian cysts Dichotomous categorical: yes, no Dichotomous categorical: yes, no 1 
Previous 
myomectomy 
Dichotomous categorical: yes, no Dichotomous categorical: yes, no 1 
Smoking status 
Derived from two questions: (Have 
you smoked at least 100 cigarettes in 
your entire life?) and (Do you smoke 
cigarettes now?) 
Nominal categorical: never; 
former; current 
2 
BMI 
Continuous BMI at baseline 
calculated as kg/m
2 
(derived from 
self-reported height in feet and inches 
and weight in pounds) 
Restricted cubic spline with 3 
knots at 18.5 (lower limit of 
“normal”), 25 (lower limit of 
“overweight”), and 30 (lower 
limit of “obese”) 
2 
Family history 
of common 
benign 
gynecologic 
disorders in 
mother and/or 
sister(s) 
Derived from a number of yes/no 
questions in the interview regarding 
endometriosis, fibroids, and ovarian 
cysts in the biological mother and/or 
sister(s). 
Dichotomous categorical: yes, no 1 
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CHAPTER 4. A POOLED ANALYSIS OF HYSTERECTOMY AND SUBTYPES OF 
EPITHELIAL OVARIAN CANCER 
 
4.1 Abstract 
 Epidemiologic studies have generally reported inverse associations between hysterectomy 
and ovarian cancer. However, recent reports indicate that ovarian cancer is a heterogeneous disease 
with histologic subtype-specific risk factors and the association with hysterectomy may be changing. 
We conducted a pooled analysis of 12,499 epithelial ovarian cancer (EOC) cases and 16,887 controls 
from 15 studies in the Ovarian Cancer Association Consortium (OCAC) to evaluate the association 
between hysterectomy and subtypes of EOC. Study-specific odds ratios (OR) were calculated by 
conditional logistic regression conditioned on age and race/ethnicity and pooled using random-effects 
models; 95% prediction intervals (PI) were calculated when between-study variance was >0. 
Hysterectomy was associated with an average relative increase of 19% in the odds (average OR 
=1.19, 95% PI: 1.05, 1.36) for invasive EOC. The average ORs for all low malignant potential (LMP) 
tumors and subtypes of LMP serous, invasive serous, invasive endometrioid, and mucinous EOC 
were above the null. There was an inverse association between hysterectomy and invasive clear cell 
EOC (average OR=0.75, 95% PI: 0.28, 2.00). Hysterectomies prior to age 40 (average OR=1.36, 95% 
PI: 1.15, 1.61) or ≥30 years in the past (average OR=1.85, 95% PI: 0.88, 3.90) were positively 
associated with invasive serous EOC. Considerable heterogeneity of results, potential biases in 
previous and/or current studies, and/or a changing association between hysterectomy and EOC may 
explain why these results do not support the long-held belief that hysterectomy is protective against 
ovarian cancer. 
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4.2 Introduction 
 Older studies have generally reported that hysterectomy, with or without unilateral 
oophorectomy, is inversely associated with, and interpreted as causally reducing, risk of EOC.
147
 
However, recent research showing that EOC is a heterogeneous disease, with risk factors differing by 
histologic subtypes,
58,61,62,105,107,108,148-151
 prompts a new examination of this hypothesis among 
different histological types of EOC. Additionally, examination of a recent meta-analysis
147
 suggests 
that the relationship between hysterectomy and EOC may be changing, though the overall conclusion 
was that hysterectomy is associated with a decrease in risk. 
 Hysterectomy is common, with ~600,000 hysterectomies performed annually in the US. 
More than one-third of women will have a hysterectomy by age 60.
2,3
 The hysterectomy rate in the 
US peaked in 1975, when more than 725,000 were performed, declined through the 1980s, leveled off 
in the 1990s, and decreased approximately 1.9% per year between 1997 and 2005.
2-6
 Hysterectomy 
rates in Australia, Europe, and the United Kingdom have also been declining in recent years and are 
lower than in the US.
9,10,152-157
 Most hysterectomies are performed for benign gynecologic conditions 
such as uterine leiomyoma, excessive bleeding, uterine prolapse, and endometriosis.
8,25
 Given that it 
is a common procedure, having a better understanding of the relationship between hysterectomy and 
EOC is important. To that end, we conducted a pooled analysis of hysterectomy and EOC subtypes 
among nearly 30,000 women from 15 recent case-control studies in the Ovarian Cancer Association 
Consortium. 
4.3 Materials and methods 
4.3.1 Data sources 
 This analysis included 15 case-control studies in the OCAC, including one from Australia,
158
 
five from Europe,
101,102,159-164
 and nine from the US.
165-178
 All studies, except two (NTH, UKO), were 
population-based and conducted between 1992 and 2010 (Table 2). The NTH study
101,102
 was limited 
to cases alive 2-19 years after diagnosis, with controls selected from a separate cross-sectional study 
conducted in the middle of the case incidence period. The UKO study
159
 included cases from 
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gynecological oncology centers and controls from an ovarian cancer screening trial. All studies had 
ethics board approval and obtained written informed consent from all participants. 
 Self-reported data for hysterectomy and other epidemiologic variables from each study were 
submitted to the OCAC data coordination center at Duke University where common coding schemes 
were applied. Non-epithelial ovarian cancer cases and epithelial cases with missing tumor behavior 
(i.e., LMP or invasive) or histology were excluded from the analysis (n=278). Additionally, women 
with missing ages at diagnosis (cases), interview/reference date (controls) or hysterectomy were 
excluded (n=669). Our analytic dataset included 2,654 women with LMP ovarian tumors, 9,845 
women with invasive EOC, and 16,887 controls. 
4.3.2 Statistical methods 
 The primary exposure was defined as hysterectomy that occurred >2 years prior to diagnosis 
(cases) or interview/reference date (controls). Women reporting hysterectomy within two years of 
diagnosis were considered ‘unexposed’ to avoid including cases whose hysterectomies were related to 
their (sub-clinical) ovarian cancer in the exposed group. We also analyzed age at hysterectomy (<40 
and >40 years) and time since hysterectomy (2- <15 years, 15- <30 years, and >30 years). 
 For primary analyses, we analyzed five case groups: LMP serous; invasive serous; invasive 
endometrioid; invasive clear cell; and mucinous (LMP and invasive combined). We also evaluated 
cases with LMP and invasive mucinous tumors separately. Similarly, we evaluated low-grade 
(grade=1/well-differentiated) and high-grade (grade=2+/moderately, poorly, or undifferentiated) 
invasive serous cancers separately (LGSC and HGSC, respectively).
109,110
 Results were similar for 
both LGSC/HGSC and LMP/invasive mucinous (Appendix Table 1). To facilitate comparisons with 
the published literature, we also analyzed all invasive EOC cases combined and all LMP tumors 
combined. 
 All estimates were adjusted for age (<40; 40- <45; 45- <50; 50- <55; 55- <60; 60- <65; 65- 
<70; 70- <75; and ≥75) and race/ethnicity (non-Hispanic white; Hispanic white; black; Asian; and 
other). We constructed causal diagrams (directed acyclic graphs (DAG))
111,112
 to identify a minimally 
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sufficient adjustment set (MSAS) for each of the different hysterectomy-outcome pairings using the 
DAG program v0.20 (http://epi.dife.de/dag/).
113
 Because the outcome groups share many risk factors, 
the MSAS were similar. For the overall LMP, LMP serous, overall invasive and invasive serous 
models, the MSAS also included: body mass index (BMI) in early adulthood (<18.5; 18.5- <25; 25- 
<30; and ≥30); number of full-term births (0; 1; 2; 3; and ≥4); duration of oral contraceptive (OC) use 
(0; <24, 24- <60; 60- <120; and ≥120 months); tubal ligation; and history of breast or ovarian cancer 
in the mother. The MSAS for the invasive endometrioid and clear cell ovarian cancer models 
additionally included self-reported endometriosis. The MSAS for the mucinous ovarian cancer 
models included only age and race. As reliable information on BMI in early adulthood and/or 
endometriosis were not collected by the NTH, POL, and STA studies, we could not adjust for these 
variables in their study-specific models. Variables evaluated but not included in the MSAS were: age 
at menarche; breastfeeding; estrogen replacement therapy; combination hormone replacement 
therapy; unilateral oophorectomy; smoking; fibroids; lifetime number of ovulatory cycles; premature 
ovarian failure; age at menopause; pelvic pain; abnormal uterine bleeding; and menopausal 
symptoms. 
 Study-specific ORs and 95% confidence intervals (CI) for the associations between 
hysterectomy and EOC subtypes were estimated using conditional logistic regression models with the 
design variables age and race/ethnicity defining the conditioning sets. For all outcome groups and 
most studies, there were no material differences between the unadjusted and adjusted effect estimates 
(results not shown); adjusted ORs are presented here. 
 Using the metareg command in Stata 9 (StataCorp LP, College Station, Texas, USA), we 
obtained estimates of the mean and variance of random-effects distributions using the restricted 
maximum likelihood method of DerSimonian and Laird
114,115
 in meta-regression models: without 
regressors (i.e., intercept-only) to get estimates of the mean and variance and with regressors to 
evaluate, one at a time, a list of study characteristics. Regarding study validity, we considered: case 
type (population-based/hospital- or clinic-based); prevalence of cases defined by mean time between 
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diagnosis and interview (≤1 year/>1 year); control sampling (concurrent with cases/after cases were 
enrolled); and enrollment of controls unsure of oophorectomy status (explicitly not enrolled because 
of indeterminate eligibility/included). We evaluated the following characteristics related to time and 
place: location (United States (US)/non-US); median year of diagnosis (≤2000/2000- ); age-
standardized prevalence of hysterectomy among controls (<15%/≥15%) as a surrogate for how 
common hysterectomy is in the source populations; and median year hysterectomies were performed 
among controls (<1980/1980- ) (Appendix Table 2). To address multiple testing in our evaluation of 
these study characteristics, we performed Monte Carlo permutation tests as described by Higgins and 
Thompson
120
 and, a priori, used a multiplicity adjusted alpha of 0.05 for identifying study 
characteristics that explained heterogeneity. 
 A random-effects model produces estimated values of the mean (𝜇) and variance (𝜏2) of a 
presumptively normal distribution of “true” values: in this case, a distribution of log ORs across 
different populations. The antilog of the distribution’s estimated mean, ?̂?, may be considered a point 
estimate of the average OR, which is reported with a 95% CI to reflect the role of sampling error. It 
remains to informatively describe the estimated variance, or spread, of the random-effects 
distribution. We do so in two ways. One is to compute the opposite effects proportion (OEP), which 
is our name for the area under the curve on the opposite side of the null value from the estimated 
mean.
116
 For instance, if ?̂? > 0, the estimate of the average OR is greater than 1 and the OEP 
estimates the proportion of populations in which the ORs are below 1. The other approach is to 
compute a 95% prediction interval (PI), which is calculated (on the log OR scale) as ?̂?  ±
 𝑡𝑘−2 √?̂?2 + 𝑆?̂?(?̂?)2 , where 𝑘 is the number of studies in the meta-analysis, 𝑡𝑘−2 is the 2.5th 
percentile of the 𝑡 distribution with 𝑘 − 2 degrees of freedom, and 𝑆?̂?(?̂?)2 is the estimated standard 
error of the sampling distribution for ?̂?.117-119 Technically, in hypothetically endless repetitions of the 
entire ensemble of 𝑘 studies, 95% of the 95% PIs cover the “true” OR to be estimated in the “next” 
study (i.e., study number 𝑘 + 1). As a practical matter, the 95% PI is attractive because its width is 
 34 
 
 
determined not only by the estimated spread of the random-effects distribution, ?̂?2, but by the 
estimated degree of random error, in the form of 𝑆𝐸(?̂?)2. When ?̂?2 > 0, the 95% PI for the next OR 
is wider than the 95% CI for the average OR. When ?̂?2 = 0, the random-effects model reduces to a 
fixed-effect model and the two intervals become identical. 
 Analyses were conducted using SAS 9.2 (SAS Institute, Cary, North Carolina, USA) and 
Stata 9. 
4.4 Results 
 Less than 1% of controls reported hysterectomy within 2 years of interview/reference date 
and were reclassified as ‘unexposed.’ Six percent of cases, a majority of which were from 3 studies 
(NTH, POL, UKO), reported hysterectomy within 2 years of diagnosis and were reclassified as 
‘unexposed’ (Appendix Table 3). Sensitivity analyses of recent hysterectomies yielded similar results 
(Appendix Table 4; Appendix Table 5). After reclassification, the unadjusted prevalence of 
hysterectomy among controls ranged from 4% (POL) to 25% in the UCI study. Among all cases, the 
prevalence of hysterectomy ranged from 3% (POL) to 23% (NCO) (Table 3). The median ages at 
hysterectomy were 39 and 40 and the median years since hysterectomy were 22 and 21 for cases and 
controls, respectively. Among the nine studies that provided reasons for hysterectomy, the most 
frequently reported reasons among cases and controls, respectively, were fibroids (40%, 37%); 
uterine bleeding problems (25%, 26%); uterine prolapse (10%, 12%); and endometriosis (8%, 7%). 
 For all invasive forms of EOC combined, hysterectomy was associated with an average 
relative increase of 19% in the odds (average OR = 1.19, Figure 1). As the study-specific estimates 
were fairly close to each other, the estimated spread of the random-effects distribution was modest 
(?̂?2=0.002, OEP<1%) and the 95% PI for the next OR (1.05, 1.36) was similar to the 95% CI for the 
average OR (1.08, 1.32) (Figure 1, Table 4). For LMP tumors, the point estimate was farther from the 
null (average OR = 1.32, Figure 2), but the estimated spread of the random-effects distribution was 
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considerably broader (?̂?2=0.07, OEP=15%). The 95% PI for the next OR (0.69, 2.52) was therefore 
noticeably wider than the 95% CI for the average OR (1.02, 1.71) (Figure 2, Table 4). 
 Considerable heterogeneity was apparent for all but one of the EOC subtypes (Table 4). The 
exception was invasive serous EOC, for which the estimated average OR of 1.20 was approximately a 
fixed-effect estimate and the 95% PI of 1.01 to 1.43 for the next OR was very similar to the 95% CI 
of 1.07 to 1.35 for the average OR. The average OR was estimated to be below the null for invasive 
clear cell EOC and above the null for the remaining subtypes, but in each case the OEP suggested the 
presence of sizable proportions of populations (from 16% for LMP serous tumors to 24% for invasive 
clear cell EOC) with associations in the opposite direction from the average (Table 4). No study 
characteristic met our predesignated criterion for explaining heterogeneity in any of the meta-
regression analyses for any subtype of EOC. 
 There was a 36% average relative increase in the odds of invasive serous EOC for women 
who had their hysterectomy before age 40 (average OR=1.36, 95% PI: 1.15, 1.61) but the average OR 
was attenuated for women who had their hysterectomy at age ≥40 (1.09, 95% CI: 0.95, 1.24) (Table 
5). There was little heterogeneity within these exposure sub-groups; the difference between them was 
significant (P=0.02). Women younger than 40 years at hysterectomy were less likely to report 
fibroids (32%) and more likely to report endometriosis (10%) as reasons for their surgery than women 
aged 40 years or more at hysterectomy (45% and 5% for fibroids and endometriosis, respectively). 
 There was an average relative increase of 85% in the odds of invasive serous EOC for women 
whose hysterectomies occurred 30 years or more in the past; this was the strongest positive 
association among the three exposure sub-groups, which produced different estimates (P<0.001) 
(Table 6). The heterogeneous results for women who had their hysterectomy <15 years in the past 
were explained by variation in the prevalence of hysterectomy among controls across the study sites 
(P=0.01). The average relative odds of invasive serous EOC were increased among women from 
studies where <15% of the controls reported hysterectomy (OR=1.34, 95% CI: 0.95, 1.89) and were 
decreased among women from studies where ≥15% of the controls reported hysterectomy (OR=0.76, 
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95% CI: 0.58, 1.00). There was no heterogeneity of results for hysterectomies performed 15-29 years 
in the past. 
4.5 Discussion 
 Contrary to earlier published results, the more recent studies included in this analysis 
generally showed positive associations between hysterectomy and most subtypes of EOC. The results 
were consistent across study sites for invasive serous EOC but there was considerable heterogeneity 
in the results for the other subtypes, as evidenced by OEP values of 16% (LMP serous) and 21% 
(invasive endometrioid). Our analyses also suggest a positive association between hysterectomy and 
mucinous tumors which is consistent with previous findings.
60,61
 The small sample size, wide PI, and 
substantial heterogeneity suggest that subsequent studies need to replicate the inverse association 
between hysterectomy and invasive clear cell EOC that we found. In general, our sample size was 
relatively small among the non-serous subtypes of EOC within each study, even with more than 
12,000 cases in total. 
 A recently published meta-analysis on the association between hysterectomy and ovarian 
cancer
147
 reported an overall average OR of 0.74 (95% CI: 0.64, 0.85) from studies published 
between 1969 and 2010. However, there was significant heterogeneity among the studies (P<0.01), 
possibly due to heterogeneous outcome groups (i.e., benign and LMP tumors, invasive EOC), and/or 
inclusion of at least one study conducted among carriers of BRCA1/2 mutations. Examination of the 
published forest plot suggests that the heterogeneity may also be due to the more recent studies, 
published after 2003. Among those, four include data from studies that are part of the present analysis 
(AUS,
179-181
 HAW,
89
 NCO,
89,182
 and NEC) and show either no association or an increase in the odds 
of EOC with hysterectomy. 
 Previously, a pooled case-control study of 2,197 cases with invasive EOC and 8,893 controls 
reported a 34% decrease in risk associated with hysterectomy among hospital-based studies but an 
attenuated 12% decrease in risk among population-based studies.
72
 Inverse associations have also 
been reported in several smaller case-control studies,
58,61,75-81
 as well as in some cohort 
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studies.
82,83,85,150
 In the Nurses’ Health Study, however, the prevalence of hysterectomy was slightly 
higher among EOC cases (14%) than among non-cases (13%); hysterectomy was only inversely 
associated with ovarian cancer after adjustment for a number of covariates, notably post-menopausal 
estrogen use (ERT).
150
 ERT use often, but not always, occurs subsequent to hysterectomy and is 
affected by hysterectomy since an intact uterus is a contraindication for ERT use. ERT use has also 
been positively associated with EOC.
183,184
 We hesitate to attribute our findings to increased ERT use 
among women with hysterectomy because ERT was also prescribed to women in previous studies 
where there was an inverse relationship between hysterectomy and EOC. Detailed information on the 
timing of and indications for each use of ERT, unavailable at the time of our analysis, is necessary to 
fully understand the relationship between hysterectomy and EOC, as it is impacted by ERT use. 
 Whittemore et al
72
 suggested that hysterectomy might impair ovarian function by 
compromising blood flow to the ovaries, resulting in anovulation. If true, hysterectomy during the 
reproductive years should confer more protection than post-menopausal hysterectomy. With the 
exception of a pooled analysis of hospital-based case-control studies
72
 and a historical cohort study in 
Canada,
83
 published studies have shown no differences in the associations between ages at 
hysterectomy and ovarian cancer.
76,78,185
 However, several studies, including a pooled analysis of 
population-based case-control studies,
72
 have reported decreased risk of ovarian cancer associated 
with increasing time between hysterectomy and diagnosis of ovarian cancer.
81,88
 In contrast, our 
results are inconsistent with previous publications; the average relative odds of invasive serous EOC 
were increased with hysterectomies occurring prior to age 40 or occurring 30 years or more before 
diagnosis. 
 With regard to age at hysterectomy, some data suggest that more recent pregnancies and OC 
use are associated with greater reductions in ovarian cancer risk.
186
 It may be that women who 
undergo a pre-menopausal hysterectomy are missing the risk lowering effects of later births and/or 
OC use. Our estimates are adjusted for number of full-term births and duration of OC use, but 
additional consideration for ages at last birth and last use of OCs, which may be on the pathway 
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between hysterectomy and ovarian cancer, may be warranted in future studies. The same scenario 
holds true for women who have a tubal ligation (i.e., earlier ages at last pregnancy and OC use), 
which is consistently shown to have an inverse association with all subtypes of EOC.
147
 In fact, 11 of 
our 15 studies were included in a recent pooled analysis that reported an inverse association 
(OR=0.71, 95% CI: 0.66, 0.77) between tubal ligation and invasive EOC.
108
 However, there may be a 
risk lowering mechanism associated with tubal ligation that is independent of those effects. 
 With regard to time since hysterectomy, Weiss and Harlow
90
 suggested that the “healthy 
screenee effect,” whereby pre-malignant/malignant ovaries/tubes are discovered and removed at the 
time of the hysterectomy, may explain inverse associations between recent hysterectomies and EOC. 
However, it is unlikely to explain our findings since we reclassified hysterectomies around the time of 
diagnosis as ‘unexposed’ to avoid hysterectomies related to malignancy. Additionally, only recently 
has there been identification of a possible precursor to EOC (i.e., p53 signature) and it is not apparent 
upon visual inspection of the upper genital tract.
187
 Ovarian endometriosis may also be considered a 
precursor to some subtypes of ovarian carcinogenesis; however, we adjusted for self-reported 
endometriosis in the invasive endometrioid and clear cell models. 
 Both hysterectomy and oophorectomy were self-reported and may be subject to 
misclassification. In the published literature, agreement between self-reported hysterectomy and 
medical records was 95% or better, with kappa statistics ranging from 0.70 to 0.93.
74,152,188-192
 Thus, it 
seems unlikely that misreporting of hysterectomy status substantially influenced the current results. 
Reporting of oophorectomy at the time of hysterectomy is less accurate.
74,189,193,194
 In one study,
189
 
agreement with medical records was 95% for women reporting hysterectomy only, 83% for 
hysterectomy with bilateral salpingo-oophorectomy (BSO), and 77% for hysterectomy with unilateral 
oophorectomy. In situations where BSO is overreported and for ovarian cancer studies which exclude 
women if they are unsure of whether or not they had a BSO, women will be excluded as potential 
controls. Since a majority of them will have had a hysterectomy, the proportion of controls with a 
hysterectomy will be underestimated, resulting in potentially positive associations between 
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hysterectomy and ovarian cancer. Though the proportions of hysterectomy among controls in the 
current studies vary by study/geographic region as expected
2
 and are generally lower than the 
prevalences of all hysterectomies (including those with concomitant BSO) in the source 
populations,
77,84,195,196
 also as expected, some women with hysterectomies may still have been 
excluded from the control groups, resulting in average ORs biased away from the null. When BSO is 
underreported, the proportion of controls with hysterectomy will be overestimated, resulting in 
potentially inverse associations between hysterectomy and ovarian cancer. Underreporting of 
oophorectomy was more likely than overreporting in some of the older studies,
74,191
 which could have 
contributed to the inverse associations between hysterectomy and ovarian cancer seen in studies 
around the same time. Most of the published validity studies of oophorectomy status occurred in the 
more distant past, when details of medical care were not always shared with patients. It is possible 
that the accuracy of self-reported oophorectomy has improved and is more accurate in these studies. 
 Concomitant bilateral salpingo-oophorectomy (BSO) was undertaken in roughly half of 
hysterectomies in the United States in the late 1990s, up from 25% in 1965; however, this rate varies 
by age.
1,5
 The American College of Obstetricians and Gynecologists recommended in 1999
12
 and 
2008
13
 that BSO be avoided in premenopausal women because of the negative outcomes associated 
with premature loss of ovarian function.
14
 Thus, only 37% of hysterectomies among women aged 15-
44 years included concomitant BSO versus 78% of hysterectomies among women aged 50-54 
years.
3,15,16
 Because loss of ovarian function is generally noticeable, misclassification of BSO status 
among women with premenopausal hysterectomy is less likely than among women with 
postmenopausal hysterectomy who have already experienced symptoms of hormone depletion. 
Because the median age at hysterectomy among controls was 40 and 90% of reported hysterectomies 
in these studies occurred before the age of 50, it is unlikely that misclassification of BSO status 
dramatically influenced our results, at least among women who had a hysterectomy prior to 
menopause. 
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 Our primary finding that hysterectomy is not inversely associated with EOC is inconsistent 
with the published literature and may be due to temporal changes in the association. The authors of a 
recent meta-analysis reported that median year of cancer diagnosis explained the significant 
heterogeneity of their results and concluded that there appears to be a temporal shift in the association 
between hysterectomy and ovarian cancer. The summary relative risk (RR) for studies with a median 
year of diagnosis prior to 2000 was 0.70 (95% CI: 0.65, 0.76) while the summary RR for studies with 
a median year of diagnosis post 2000 was 1.18 (1.06, 1.31).
197
 The median year of diagnosis among 
our studies ranged from 1994 to 2005 (Appendix Table 2) but did not explain any heterogeneity of 
results for any of the subtypes of EOC. It remains unclear what would underlie a temporal change. 
Indications for hysterectomy have not radically changed over the past several decades and it seems 
unlikely that unmeasured confounding by indication could explain our results, especially since uterine 
fibroids, bleeding, and prolapse have not been shown to be associated with EOC. However, as 
alternative therapies are used to treat such conditions, symptoms may need to be more severe before 
hysterectomies are indicated. Theoretically, increased severity of benign gynecologic conditions 
could potentially be related to ovarian cancer risk. It is imperative that the relationships among 
hysterectomy, gynecologic conditions, and ovarian cancer are carefully considered in future studies, 
especially as trends in the surgical approach to hysterectomy move from abdominal to laparoscopic, 
the age at hysterectomy increases,
198
 and if women with gynecologic conditions, specifically those 
requiring hysterectomy, are more likely to participate as controls in studies. 
 In this pooled analysis of almost 30,000 women from 15 studies, hysterectomy was positively 
associated with increased average odds of all histologic subtypes of EOC except invasive clear cell; 
however, there was considerable heterogeneity that we could not explain. Increased average odds of 
invasive serous EOC were associated with hysterectomy before the age of 40 or ≥30 years before 
diagnosis/interview. These findings are also inconsistent with the published literature and may be due 
to biases in the previous (or current) studies or a changing association between hysterectomy and 
EOC. Future research should carefully classify women according to their oophorectomy status, 
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account for how the ovarian cancer cases were diagnosed (e.g., at the time of hysterectomy), and 
consider the downstream consequences of hysterectomy (e.g., timing of the use of OCs and ERT). 
Medical records of all potential controls reporting hysterectomy may have to be reviewed in order to 
exclude women who had a concomitant BSO and to understand the circumstances surrounding their 
hysterectomies. Additional research into the indications for hysterectomy and their relation to ovarian 
cancer risk may also be warranted. Until additional research can be done, clinicians should be aware 
that recent evidence does not support the long-held belief that hysterectomy confers some protection 
against all types of EOC. 
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Table 2. Description of 15 case-control studies included in the analyses of hysterectomy and epithelial ovarian tumors from the Ovarian Cancer 
Association Consortium 
Study 
Acronym 
Study Name Location 
Period of 
Ascertainment 
Method(s) of 
Data Collection
a
 
Response Rates
b
 
Cases Controls 
AUS
158
 
Australian Ovarian Cancer Study & 
Australian Cancer Study (Ovarian Cancer)
c
 
Australia 2002-2006 Questionnaire 65% 47% 
CON
165
 Connecticut Ovarian Cancer Study USA 1998-2003 Interview 69% 61% 
DOV
166
 Diseases of the Ovary and their Evaluation USA 2002-2009 Interview 74% 62% 
GER
163
 German Ovarian Cancer Study Germany 1993-1996 Questionnaire 58% 51% 
HAW
167,168
 
Hawaii Ovarian Cancer Case-Control 
Study 
USA 1993-2008 Interview 78% 80% 
HOP
169
 
Novel Risk Factors and Potential Early 
Detection Markers for Ovarian Cancer 
USA 2003-2009 Interview 71% 68% 
MAL
161,162,164
 Malignant Ovarian Cancer Study Denmark 1994-1999 Interview 81% 68% 
NCO
170,171
 North Carolina Ovarian Cancer Study USA 1999-2008 Interview 67% 60% 
NEC
172,173
 
New England Case-Control Study of 
Ovarian Cancer 
USA 1992-2003 Interview 71% 64% 
NTH
101,102
 Nijmegen Ovarian Cancer Study Netherlands 
2008 (cases); 
2002-2003 
(controls) 
Questionnaire 63% 42% 
POL
160
 Polish Ovarian Cancer Case Control Study Poland 2000-2003 Interview 78% 69% 
STA
174
 
Genetic Epidemiology of Ovarian Cancer 
Study 
USA 1997-2001 Interview 75% 75% 
UCI
175
 
University of California Irvine Ovarian 
Study 
USA 1993-2005 
Interview or 
Questionnaire 
67% 80% 
UKO
159
 
United Kingdom Ovarian Cancer 
Population Study 
UK 
2006-2010 
(cases); 2000-
2005 (controls) 
Interview 86% 97% 
USC
176-178
 
Los Angeles County Case-Control Studies 
of Ovarian Cancer 
USA 1992-2002 Interview 60% 72% 
UK=United Kingdom; USA=United States of America. 
a
 Questionnaires were self-completed by the study participant; Interviews were administered either in person or over the phone. 
b
 Response rates were calculated differently across studies; algorithms are available upon request. 
c
 Combined for the purpose of the analysis. 
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Table 3. Counts of cases and controls with hysterectomy more than two years prior to diagnosis (cases) or interview/reference date 
(controls) according to study and subtype of epithelial ovarian tumors for 15 studies from the Ovarian Cancer Association Consortium 
Study Controls All LMP All Invasive 
LMP 
Serous 
Invasive 
Serous 
Invasive 
Endometrioid 
Invasive 
Clear Cell 
Mucinous
a
 Other
b
 
AUS 281/1,488 (19) 61/306 (20) 255/1,114 (23) 28/143 (20) 163/682 (24) 27/134 (20) 18/86 (21) 38/193 (20) 42/182 (23) 
CON 59/549 (11) 15/107 (14) 51/369 (14) 12/68 (18) 28/219 (13) 10/72 (14) 3/35 (9) 9/54 (17) 4/28 (14) 
DOV 342/1,849 (18) 75/417 (18) 234/1,159 (20) 46/235 (20) 164/675 (24) 23/187 (12) 5/88 (6) 28/191 (15) 43/200 (22) 
GER 130/533 (24) 3/30 (10) 47/228 (21) 2/18 (11) 21/114 (18) 5/26 (19) 1/6 (17) 6/36 (17) 15/58 (26) 
HAW 109/1,104 (10) 16/187 (9) 94/709 (13) 11/89 (12) 48/315 (15) 15/117 (13) 8/82 (10) 11/162 (7) 17/131 (13) 
HOP 298/1,804 (17) 19/97 (20) 126/674 (19) 14/58 (24) 74/364 (20) 21/97 (22) 4/52 (8) 7/65 (11) 25/135 (19) 
MAL 139/1,564 (9) 20/202 (10) 79/553 (14) 12/104 (12) 46/342 (13) 13/75 (17) 7/44 (16) 14/138 (10) 7/52 (13) 
NCO 242/1,081 (22) 35/225 (16) 214/867 (25) 24/158 (15) 137/472 (29) 30/140 (21) 11/90 (12) 16/107 (15) 31/125 (25) 
NEC 100/1,243 (8) 21/294 (7) 69/825 (8) 11/173 (6) 47/462 (10) 9/167 (5) 8/112 (7) 9/154 (6) 6/51 (12) 
NTH 79/594 (13) N/A
c
 36/255 (14) N/A
c
 20/116 (17) 5/65 (8) 3/18 (17) 4/34 (12) 4/22 (18) 
POL 47/1,101 (4) 0/21 (0) 8/272 (3) 0/17 (0) 4/123 (3) 0/40 (0) 1/11 (9) 1/22 (5) 2/80 (3) 
STA 55/566 (10) 11/161 (7) 47/499 (9) 8/105 (8) 32/262 (12) 3/60 (5) 0/51 (0) 6/88 (7) 9/94 (10) 
UCI 145/569 (25) 21/197 (11) 101/392 (26) 12/122 (10) 64/213 (30) 16/72 (22) 4/37 (11) 15/102 (15) 11/43 (26) 
UKO 198/1,033 (19) N/A
c
 92/603 N/A
c
 44/310 (14) 22/96 (23) 6/56 (11) 10/60 (17) 10/81 (12) 
USC 205/1,809 (11) 46/410 (11) 233/1,326 (18) 31/243 (13) 158/833 (19) 28/183 (15) 10/87 (11) 34/274 (12) 18/116(16) 
All  2,429/16,887 343/2,654 1,686/9,845 211/1,533 1,050/5,502 227/1,531 89/855 208/1,680 244/1,398 
LMP=low malignant potential; N/A=not applicable. 
a 
Includes low malignant potential and invasive epithelial ovarian cancers of mucinous histology. 
b
 Includes mixed cell, other specified epithelial ovarian cancer (e.g., Brenner tumor), undifferentiated or poorly differentiated epithelial ovarian 
cancer and known epithelial ovarian cancer of unknown histology. Both low malignant potential and invasive behaviors are included.  
c 
Study only enrolled invasive epithelial ovarian cancer cases; no cases of low malignant potential are included. 
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Table 4. Association between hysterectomy more than two years prior to diagnosis (cases) or interview/reference date (controls) and 
subtypes of epithelial ovarian tumors in 15 studies from the Ovarian Cancer Association Consortium 
Study 
All LMP 
Combined
a
 
All Invasive 
Combined
a
 
LMP Serous
a
 Invasive Serous
a
 
Invasive 
Endometrioid
b
 
Invasive Clear 
Cell
b
 
Mucinous
c
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
AUS 1.85 1.28, 2.67 1.20 0.96, 1.49 1.82 1.09, 3.05 1.14 0.89, 1.47 0.94 0.55, 1.60 0.85 0.44, 1.65 1.72 1.13, 2.60 
CON 1.60 0.81, 3.16 1.28 0.82, 2.00 2.22 1.01, 4.87 0.99 0.58, 1.70 1.05 0.46, 2.39 0.63 0.15, 2.58 1.71 0.76, 3.83 
DOV 1.40 1.03, 1.90 1.27 1.03, 1.55 1.56 1.06, 2.28 1.41 1.12, 1.77 0.87 0.53, 1.44 0.28 0.11, 0.73 1.00 0.65, 1.54 
GER 0.52 0.11, 2.47 0.83 0.54, 1.29 0.59 0.07, 5.35 0.57 0.31, 1.04 0.85 0.27, 2.65 1.33 0.10, 17.11 0.88 0.34, 2.29 
HAW 1.42 0.77, 2.62 1.33 0.96, 1.82 2.10 0.98, 4.50 1.32 0.90, 1.95 1.35 0.70, 2.62 1.07 0.46, 2.45 0.95 0.48, 1.85 
HOP 2.25 1.26, 4.00 1.21 0.94, 1.54 3.61 1.77, 7.35 1.21 0.89, 1.64 1.66 0.96, 2.86 0.44 0.14, 1.33 0.76 0.34, 1.72 
MAL
d
 1.25 0.75, 2.08 1.55 1.14, 2.12 1.35 0.71, 2.58 1.42 0.97, 2.07 2.04 1.04, 4.01 2.07 0.86, 4.95 1.22 0.68, 2.18 
NCO 1.13 0.72, 1.77 1.07 0.84, 1.37 0.99 0.58, 1.69 1.25 0.95, 1.65 0.85 0.51, 1.41 0.35 0.16, 0.77 0.92 0.51, 1.64 
NEC 1.52 0.89, 2.60 1.05 0.74, 1.48 1.52 0.76, 3.05 1.08 0.73, 1.61 0.74 0.35, 1.58 0.89 0.40, 2.00 1.00 0.48, 2.06 
NTH
e
 N/A N/A 1.27 0.73, 2.22 N/A N/A 1.42 0.72, 2.81 0.53 0.15, 1.86 4.39 0.58, 32.95 1.30 0.42, 4.07 
POL
f
 N/A N/A 0.54 0.23, 1.27 N/A N/A 0.59 0.17, 2.01 N/A N/A 2.16 0.23, 20.01 1.08 0.14, 8.37 
STA
g
 1.02 0.45, 2.32 0.72 0.45, 1.17 0.96 0.38, 2.42 0.80 0.47, 1.39 0.63 0.17, 2.33 N/A N/A 0.95 0.33, 2.70 
UCI 0.44 0.24, 0.81 0.96 0.63, 1.45 0.41 0.19, 0.87 1.11 0.68, 1.80 0.88 0.40, 1.93 0.26 0.06, 1.09 0.56 0.30, 1.06 
UKO N/A N/A 1.21 0.88, 1.67 N/A N/A 0.88 0.58, 1.34 1.28 0.47, 3.47 0.98 0.30, 3.18 1.47 0.69, 3.14 
USC 1.44 0.98, 2.11 1.44 1.15, 1.79 1.60 1.01, 2.53 1.45 1.14, 1.85 1.44 0.89, 2.32 0.74 0.33, 1.67 1.43 0.94, 2.19 
Random 
Effects 
1.32 1.02, 1.71 1.19 1.08, 1.32 1.45 1.03, 2.03 1.20 1.07, 1.35 1.09 0.89, 1.35 0.75 0.50, 1.12 1.12 0.91, 1.38 
?̂?𝟐 0.07088 0.001531 0.1349 0.003611 0.01206 0.1683 0.02559 
95% PI 0.69 to 2.52 1.05 to 1.36 0.60 to 3.52 1.01 to 1.43 0.79 to 1.51 0.28 to 2.00 0.75 to 1.68 
OEP 15% <1% 16% <1% 21% 24% 23% 
CI=confidence interval; LMP=low malignant potential; N/A=not available; OEP=opposite effects proportion; OR=odds ratio; PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals for the association between hysterectomy more than two years prior to diagnosis or interview/reference date 
and all LMP tumors combined, all invasive EOC combined, LMP serous tumors, and invasive serous EOC were estimated by conditional logistic 
regression models stratified by age in 5-year groups and race/ethnicity (non-Hispanic white, Hispanic white, black, Asian, other) and adjusted for body 
mass index in early adulthood (<18.5, 18.5-<25, 25-<30, ≥30), parity (0, 1, 2, 3, 4+ full-term births), duration of oral contraceptive use (0, <24 months, 
24-<60 months, 60-<120 months, ≥120 months), tubal ligation (yes/no), and history of breast or ovarian cancer in the mother (yes/no). 
b
 Conditional logistic regression models for the association between hysterectomy more than 2 years prior to diagnosis or interview/reference date and 
invasive endometrioid and invasive clear cell EOC are adjusted for endometriosis (yes/no) in additional to the covariates in the models for all LMP tumors 
combined, all invasive EOC combined, LMP serous tumors, and invasive serous EOC. 
c
 Includes LMP tumors and invasive EOC of mucinous histology. The conditional logistic regression model for the association between hysterectomy 
more than two years prior to diagnosis or interview/reference date and mucinous epithelial ovarian cancer is stratified by age in 5-year groups and 
race/ethnicity (non-Hispanic white, Hispanic white, black, Asian, other); model is not adjusted for any additional covariates. 
d
 Models for MAL all LMP tumors combined and LMP serous are not adjusted for history of breast or ovarian cancer in the mother due to missing data. 
e
 Models for NTH are not adjusted for body mass index in early adulthood. 
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f
 Models for POL are not adjusted for endometriosis. 
g
 Models for STA are not adjusted for body mass index in early adulthood or endometriosis. 
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Table 5. Association
a
  between age at hysterectomy and invasive serous epithelial ovarian cancer in 15 
studies from the Ovarian Cancer Association Consortium 
Study 
No 
Hysterectomy 
(Referent) 
Hysterectomy at <40 Years of Age 
Hysterectomy at ≥40 Years of 
Age 
Ca/Cn Ca/Cn OR 95% CI Ca/Cn OR 95% CI 
AUS 519/1,207 68/101 1.40 0.98, 2.00 95/180 0.99  0.73, 1.35 
CON 191/490 10/27 1.01 0.45, 2.29 18/32 0.98  0.50, 1.93 
DOV 511/1,507 114/196 1.70 1.30, 2.22 50/146 1.00  0.70, 1.43 
GER 93/403 3/35 0.24 0.06, 1.07 18/95 0.70  0.36, 1.33 
HAW 267/995 25/48 1.52 0.90, 2.58 23/61 1.16 0.68, 1.96 
HOP 290/1,506 37/154 1.13 0.76, 1.70 37/144 1.29 0.86, 1.94 
MAL 296/1,425 16/48 1.54 0.85, 2.79 30/91 1.36 0.85, 2.16 
NCO 335/839 85/156 1.23 0.89, 1.71 52/86 1.29 0.84, 1.96 
NEC 415/1,143 25/49 1.30 0.77, 2.20 22/51 0.90 0.51, 1.56 
NTH
b
 96/515 5/19 1.33 0.35, 5.02 15/60 1.44 0.68, 3.08 
POL 119/1,054 2/8 1.29 0.14, 12.05 2/39 0.46 0.11, 2.02 
STA
b
 230/511 19/31 0.93 0.47, 1.85 13/24 0.66 0.30, 1.46 
UCI 149/424 25/54 1.68 0.83, 3.41 39/91 0.85 0.48, 1.53 
UKO 266/835 18/74 0.86 0.46, 1.62 26/124 0.89 0.53, 1.50 
USC 675/1,604 75/91 1.56 1.11, 2.19 83/114 1.36 0.99, 1.87 
 
Random Effects 
 
1.36 (1.18, 1.56) 
 
1.09 (0.95, 1.24) 
𝝉𝟐 0.0018 0 
95% PI 1.15 to 1.61 N/A 
OEP <1% N/A 
Ca=case; CI=confidence interval; Cn=control; N/A=not applicable; OEP=opposite effects proportion; OR=odds 
ratio; PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals were estimated by conditional logistic regression models stratified by 
age in 5-year groups and race/ethnicity (non-Hispanic white, Hispanic white, black, Asian, other) and adjusted for 
body mass index in early adulthood (<18.5, 18.5-<25, 25-<30, ≥30), parity (0, 1, 2, 3, 4+ full-term births), 
duration of oral contraceptive use (0, <24 months, 24-<60 months, 60-<120 months, ≥120 months), tubal ligation 
(yes/no), and history of breast or ovarian cancer in the mother (yes/no). 
b
 Models for NTH and STA are not adjusted for body mass index in early adulthood. 
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Table 6. Association
a
 between time since hysterectomy and invasive serous epithelial ovarian cancer in 15 studies 
from the Ovarian Cancer Association Consortium 
Study 
No 
Hysterectomy
(Referent) 
Hysterectomy 2- <15 years 
in the past 
Hysterectomy 15- <30 years 
in the past 
Hysterectomy ≥30 years in 
the past 
Ca/Cn Ca/Cn OR 95% CI Ca/Cn OR 95% CI Ca/Cn OR 95% CI 
AUS 519/1,207 40/96 0.86 0.56, 1.32 91/133 1.38 1.00, 1.91 32/52 1.08 0.65, 1.79 
CON 191/490 11/21 1.55 0.67, 3.59 12/25 0.81 0.37, 1.77 5/13 0.69 0.21, 2.20 
DOV 511/1,507 22/94 0.70 0.43, 1.16 74/179 1.19 0.87, 1.62 68/69 3.36 2.26, 5.01 
GER 93/403 6/58 0.38 0.14, 1.02 13/68 0.71 0.34, 1.52 2/4 0.86 0.08, 8.80 
HAW 267/995 10/22 1.63 0.74, 3.61 16/56 0.78 0.43, 1.43 22/31 2.28 1.20, 4.33 
HOP 290/1,506 10/65 0.89 0.43, 1.85 28/130 1.11 0.72, 1.73 36/103 1.50 0.96, 2.34 
MAL 296/1,425 11/54 0.79 0.39, 1.60 25/70 1.66 1.01, 2.74 10/15 2.77 1.14, 6.71 
NCO 335/839 22/56 1.01 0.58, 1.76 70/118 1.28 0.89, 1.84 45/68 1.41 0.88, 2.26 
NEC 415/1,143 16/32 1.21 0.62, 2.35 11/48 0.50 0.25, 1.00 20/20 2.44 1.23, 4.82 
NTH
b
 96/515 8/23 1.56 0.55, 4.49 9/52 1.13 0.45, 2.82 3/4 3.44 0.53, 22.51 
POL 119/1,054 3/23 0.89 0.20, 4.11 0/20   1/4 2.38 0.21, 27.46 
STA
b
 230/511 10/19 0.87 0.35, 2.13 20/29 0.86 0.43, 1.72 2/7 0.38 0.07, 2.10 
UCI 149/424 9/59 0.40 0.16, 0.98 30/62 1.16 0.61, 2.21 25/24 4.54 1.58, 13.03 
UKO 266/835 13/44 0.64 0.27, 1.52 20/120 0.77 0.44, 1.34 11/34 1.70 0.76, 3.76 
USC 675/1,604 37/54 1.59 1.01, 2.51 82/117 1.24 0.90, 1.71 39/34 1.94 1.17, 3.21 
 
Random Effects 
 
0.95 (0.75, 1.19) 
 
1.13 (0.97, 1.32) 
 
1.85 (1.39, 2.46) 
𝝉𝟐 0.4439 0 0.1015 
95% PI 0.57 to 1.58 N/A 0.88 to 3.90 
OEP 39% N/A 3% 
Ca=case; CI=confidence interval; Cn=control; N/A=not applicable; OEP=opposite effects proportion; OR=odds ratio; 
PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals were estimated by conditional logistic regression models stratified by age in 5-
year groups and race/ethnicity (Non-Hispanic white, Hispanic white, black, Asian, other) and adjusted for body mass index in 
early adulthood (<18.5, 18.5-<25, 25-<30, ≥30), parity (0, 1, 2, 3, 4+ full-term births), duration of oral contraceptive use (0, 
<24 months, 24-<60 months, 60-<120 months, ≥120 months), tubal ligation (yes/no), and history of breast or ovarian cancer 
in the mother (yes/no). 
b
 Models for NTH and STA are not adjusted for body mass index in early adulthood. 
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Figure 1. Results from a random-effects analysis of hysterectomy more than two years prior to 
diagnosis (cases) or interview/reference date (controls) and invasive epithelial ovarian cancer in 15 
studies in the Ovarian Cancer Association Consortium. The solid circles are centered on the study-
specific odds ratio (OR) estimates; the horizontal line through each circle indicates the 95% 
confidence interval (CI) for the study-specific estimate. The center of the diamond indicates the 
estimated average OR of a presumptively normal distribution of true values. The horizontal tips of the 
diamond indicate the 95% CI for the estimated average OR and the horizontal line through the 
diamond indicates the 95% prediction interval (PI) for the “next” study. Study-specific conditional 
logistic regression models were conditioned on age and race/ethnicity and adjusted for body mass 
index in early adulthood, number of full-term births, duration of oral contraceptive use, tubal ligation, 
and history of breast or ovarian cancer in the mother. See Table 2 for published references for each 
study. (AUS, Australian Ovarian Cancer Study and Australian Cancer Study (Ovarian Cancer); CON, 
Connecticut Ovarian Cancer Study; DOV, Diseases of the Ovary and their Evaluation; GER, German 
Ovarian Cancer Study; HAW, Hawaii Ovarian Cancer Case-Control Study; HOP, Novel Risk Factors 
and Potential Early Detection Markers for Ovarian Cancer; MAL, Malignant Ovarian Cancer Study; 
NCO, North Carolina Ovarian Cancer Study; NEC, New England Case-Control Study of Ovarian 
Cancer; NTH, Nijmegen Ovarian Cancer Study; POL, Polish Ovarian Cancer Case Control Study; 
STA, Genetic Epidemiology of Ovarian Cancer Study; UCI, University of California Irvine Ovarian 
Study; UKO, United Kingdom Ovarian Cancer Population Study; USC, Los Angeles County Case-
Control Studies of Ovarian Cancer).  
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Figure 2. Results from a random-effects analysis of hysterectomy more than two years prior to 
diagnosis (cases) or interview/reference date (controls) and low malignant potential epithelial ovarian 
tumors in 12 studies in the Ovarian Cancer Association Consortium. The solid circles are centered on 
the study-specific odds ratio (OR) estimates; the horizontal line through each circle indicates the 95% 
confidence interval (CI) for the study-specific estimate. The center of the diamond indicates the 
estimated average OR of a presumptively normal distribution of true values. The horizontal tips of the 
diamond indicate the 95% CI for the estimated average OR and the horizontal line through the 
diamond indicates the 95% prediction interval (PI) for the “next” study. Study-specific conditional 
logistic regression models were conditioned on age and race/ethnicity and adjusted for body mass 
index in early adulthood, number of full-term births, duration of oral contraceptive use, tubal ligation, 
and history of breast or ovarian cancer in the mother. See Table 2 for published references for each 
study. (AUS, Australian Ovarian Cancer Study and Australian Cancer Study (Ovarian Cancer); CON, 
Connecticut Ovarian Cancer Study; DOV, Diseases of the Ovary and their Evaluation; GER, German 
Ovarian Cancer Study; HAW, Hawaii Ovarian Cancer Case-Control Study; HOP, Novel Risk Factors 
and Potential Early Detection Markers for Ovarian Cancer; MAL, Malignant Ovarian Cancer Study; 
NCO, North Carolina Ovarian Cancer Study; NEC, New England Case-Control Study of Ovarian 
Cancer; STA, Genetic Epidemiology of Ovarian Cancer Study; UCI, University of California Irvine 
Ovarian Study; USC, Los Angeles County Case-Control Studies of Ovarian Cancer). 
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CHAPTER 5. RISK PREDICTION FOR PREMENOPAUSAL HYSTERECTOMY WITH 
THE INTENTION OF OVARIAN CONSERVATION 
5.1 Abstract 
 We sought to develop and internally validate a predictive model for hysterectomy with 
ovarian conservation among premenopausal women. We also evaluated the contribution of family 
history of benign gynecologic conditions to the model because it may be a proxy for more severe 
conditions that require invasive treatment such as hysterectomy. The study included 457 
premenopausal women who had undergone hysterectomy for benign conditions (cases) and 499 
premenopausal women attending general medicine and gynecology practices in the catchment area of 
Durham, North Carolina who had not undergone hysterectomy (controls). We fit unconditional 
logistic regression models including the following regressors to predict hysterectomy: age, race, 
marital status, body size, and history of education, smoking, oral contraceptive use, full-term 
pregnancies, tubal ligation, fibroids, endometriosis, ovarian cysts, myomectomy, and benign 
gynecologic conditions in the immediate family. Model performance was evaluated by discrimination 
(area under the receiver operating characteristic curves (AUC)) and calibration (goodness-of-fit test 
and plots of observed versus predicted probabilities) metrics. Contribution of family history to the 
model was assessed by comparing the AUCs of the models without and with the variable and 
calculating net reclassification improvement (NRI). We internally validated the model by repeating 
the model fit in 200 bootstrap samples to produce bias-corrected AUC values. Both models (without 
and with family history) exhibited very good discriminatory power (bias-corrected AUC=0.84), and 
were not poorly calibrated (goodness-of-fit p=0.2). A test of the hypothesis of no difference in AUC 
yielded p=0.1. In the NRI analysis, the net proportions reclassified correctly were <1% for cases and 
1% for controls. Family history resulted in slightly worsened classification. This initial prediction 
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model for premenopausal, ovarian-conserving hysterectomy warrants additional development, 
especially among women followed longitudinally for the occurrence of hysterectomy. Such models 
have the potential of identifying women for earlier and less invasive treatment than hysterectomy for 
benign conditions. Prediction models may also enhance the selection of participants for studies of 
hysterectomy and the imputation of missing data in studies in which hysterectomy is an outcome, 
exposure, or covariate. 
5.2 Introduction 
 Hysterectomy is the most common non-obstetric, surgical procedure among women in the 
United States (US).
1
 Although numbers of hysterectomy in the US have declined from their peak of 
725,000 in 1975, approximately 600,000 hysterectomies are currently performed annually in the US. 
More than one-third of women will have a hysterectomy by age 60.
2-6
 Younger women who undergo 
hysterectomy are more likely to do so for uterine leiomyomas, while for older women the indication 
is more likely to be prolapse or cancer.
5
 The American College of Obstetricians and Gynecologists 
recommended in 1999
12
 and 2008
13
 that bilateral salpingo-oophorectomy (BSO) be avoided in 
premenopausal women because negative outcomes associated with earlier loss of ovarian function 
outweigh the potential benefits of avoiding future ovarian pathology including ovarian cancer.
14
 Thus, 
between 2000 and 2004, only 37% of hysterectomies among women aged 15-44 years included 
concomitant BSO versus 78% of hysterectomies among women aged 50-54 years.
3,15,16
 
 In a study of the 2003 Nationwide Inpatient Sample of discharge data in a 20% stratified 
sample of US hospitals, the most frequent indications for hysterectomy were fibroids (33%), 
menstrual disorders (21%), uterine prolapse (16%), and endometriosis (14%) among white women 
aged 16 or older; among African American women aged 16 or older, hysterectomies were 
predominantly performed to treat fibroids (70%) rather than menstrual disorders (12%), uterine 
prolapse (4%), or endometriosis (6%).
11
 
 The most common indications for hysterectomy appear to have a familial component. 
Women with fibroids and with endometriosis are more likely to report a family history of these 
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conditions in first degree relatives. Women with fibroids who have a family history of fibroids may 
be more likely than women without a family history to present with more severe symptoms, and thus 
be more likely to undergo hysterectomy
43,44 
and at an earlier age.
45
 In a recent study, women with 
pathologically confirmed endometriosis were more likely to report a family history of endometriosis 
than women without endometriosis; however, the investigators did not find differences in the 
characteristics or symptoms of the women with endometriosis by family history of endometriosis.
40
 
Earlier studies have also reported associations between family history of endometriosis and clinically-
confirmed endometriosis
49,199-201
 and suggested that the severity of endometriosis may be higher 
among women with a family history of endometriosis.
49,202
 
 Although it is generally assumed that women with fibroids, endometriosis, uterine prolapse, 
and other menstrual-related conditions choose to undergo hysterectomy for treatment of their benign 
gynecologic condition(s), there is a need to precisely estimate the multivariable predictive capability 
of these potential predictors of hysterectomy and to further evaluate any other additional traits, 
including family history of common, benign gynecologic conditions. These predictive models may 
help identify at-risk women for clinical monitoring and potentially earlier (and less invasive) 
treatment. To the best of our knowledge, there have been no prediction models developed for 
hysterectomy among premenopausal women who intend to conserve one or both ovaries. To that end, 
we used data from a prospective cohort study of premenopausal women undergoing hysterectomy and 
control women with intact uteri and ovaries to develop a predictive model for hysterectomy with the 
intention of ovarian conservation. Because family history of gynecologic conditions may be a proxy 
for more severe indications for hysterectomy, we also sought to evaluate the contribution of family 
history of common, benign gynecologic conditions to the model’s performance. 
5.3 Materials and methods 
5.3.1 Study population and data sources 
 Data for the analyses came from the Prospective Research on Ovarian Function (PROOF) 
Study, a prospective cohort of premenopausal women that enrolled women in Durham, North 
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Carolina from April 2004 through December 2007.
34,121-123
 Women between the ages of 30 and 47 
years undergoing hysterectomy at Duke University Medical Center or Durham Regional Hospital, 
both part of the Duke University Health System and located in Durham, were enrolled. Women with 
intact uteri were recruited using brochures and advertisements in publications that were placed in 
clinics and offices of gynecology and family medicine practices and were frequency matched to the 
women undergoing hysterectomy on age and race. The aims of the original study were to 
prospectively determine whether women undergoing hysterectomy were more likely to experience 
ovarian failure during the four years after hysterectomy than the women with intact uteri and to 
identify medical, reproductive, and lifestyle characteristics that may be associated with earlier ovarian 
failure.
121
 The present analysis includes only baseline data for the women who underwent 
hysterectomy, hereafter identified as cases, and the women with intact uteri, hereafter identified as 
controls. 
 Cases were women, aged 30 to 47 years at baseline, who were scheduled to undergo 
hysterectomy for benign gynecologic conditions. In addition, they could not be pregnant, were 
premenopausal as evidenced by at least one menstrual period in the previous 3 months, had to have at 
least one intact ovary prior to and following the hysterectomy, had no personal history of cancer 
(except nonmelanoma skin cancer), and had to be able to complete the interview in English. 
Premenopausal status was confirmed by a pre-operative blood level of follicle-stimulating hormone 
less than 40 international units per liter. Controls had the same eligibility criteria as the cases. 
 Participants completed a baseline interview visit during which they completed an extensive 
interviewer-administered questionnaire, provided a blood specimen, and had anthropometric 
measurements taken. The baseline interview for cases occurred prior to their hysterectomies, most at 
the time of their pre-operative visits. The questionnaire ascertained information on the following: 
demographics, menstrual cycle history, reproductive history, medical and gynecologic condition 
history, family history (mothers, sisters) of benign gynecologic conditions, and lifestyle 
characteristics related to alcohol, smoking, diet, and physical activity. The study protocol was 
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approved by the Duke University Medical Center’s Institutional Review Board and all participants 
provided written, informed consent. 
5.3.2 Predictors 
 Based on a review of the scientific literature, we selected the following predictors and 
parameterizations, a priori, for inclusion in the prediction model: age (continuous, linear); self-
identified race (white, black, other); marital status (single/never married, married/living with 
significant other, divorced/separated/widowed); education level (high school graduate or lower, some 
college or post-high school training, college graduate or higher); tubal ligation (yes, no); fibroids (yes, 
no); endometriosis (yes, no); ovarian cysts (yes, no), previous myomectomy (yes, no); and smoking 
status (never, former, current). Because it has been reported that dichotomization of predictors results 
in a loss of discriminative ability
124,125
, we included the following variables as restricted cubic 
splines:
126
 duration of oral contraceptive (OC) use (knots at 1, 3, 5, and 10 years); number of full-term 
pregnancies (knots at 1, 2, and 3 pregnancies); and BMI (knots at 18.5, 25, and 30). To evaluate the 
contribution of family history to the prediction model, we included a dichotomous variable that 
indicated a history of common, benign gynecologic conditions (i.e., fibroids, endometriosis, or 
ovarian cysts) in the woman’s mother or sisters. 
5.3.3 Model specification, estimation, and performance 
 We used unconditional logistic regression; coefficients were estimated with maximum 
likelihood methods. The baseline model (model A) included the predictors outlined above except 
family history; family history was added to form the full model (model B). 
 We evaluated model performance by examining both discrimination and calibration.
133,134
 
Discrimination, the ability of the model to classify women with and without hysterectomy correctly, 
is most commonly assessed using the concordance statistic (c statistic), a rank-order statistic for 
predictions against actual outcomes. For a binary outcome, the c statistic is equivalent to the area 
under the receiver operating characteristic curve (AUC). It is interpreted as the probability that a 
randomly drawn case will have a higher predicted probability of being a case from the fitted model 
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than a randomly drawn control. The discrimination slope, which can be visualized with a box plot or 
histogram, is calculated as the difference in average predicted probabilities for women with and 
without hysterectomy.
135
 
 Calibration, the agreement between the observed and predicted outcomes, was assessed with 
the Hosmer-Lemeshow Goodness of Fit (GOF) test, a chi-squared test based on the grouping of 
similar participants into n strata (often 10, as here) on the basis of their predicted probabilities, and 
the graphical representation of observed versus predicted agreement.
203
 Additionally, we estimated 
the intercept and slope of the calibration line in a logistic regression model by regressing the observed 
outcome on the linear predictor (i.e., the predicted probabilities). Ideally, if the observed distributions 
of outcomes and predicted probabilities agree perfectly, the intercept of that line is 0 and the slope is 
1.
136
 
5.3.4 Model validation 
 Internal validation, the validity of the model in the underlying population that the data came 
from, may address issues of stability in predictor selection and quality of the predictions. The 
apparent performance of a prediction model is always better in the training/development data set than 
it is in a validation set, even when both come from the same population. The magnitude of this 
“optimism” can be used to correct performance metrics such as the AUC. 
 As an alternative to a split-sample approach, in which part of the study population is used to 
develop the prediction model and the remainder is used to validate it, we employed cross-validation 
with bootstrapping methods, which result in stable and nearly unbiased estimates of performance, as 
well as the lowest root mean squared error across methods.
137
 We generated 200 bootstrap samples 
(i.e., with replacement) from the set of study participants with non-missing predictor data,
137,138
 fitted 
the logistic regressions for models A and B in each sample, and generated a set of 200 c statistics (i.e., 
AUCs). The average of the 200 differences between the original AUC and the bootstrap samples’ 
AUCs reflects the optimism of the prediction model. The optimism-corrected AUC was then 
calculated by subtracting the optimism from the AUC estimate from the original model.
134
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5.3.5 Evaluation of family history’s contribution to the model 
 Whether the addition of the family history information substantially improved prediction was 
examined by calculating the difference between model A’s AUC and model B’s AUC.140 
Additionally, we present a reclassification table,
142
 overall and stratified by outcome,
143
 which shows 
how many cases and controls were reclassified, overall and correctly, by adding family history to the 
prediction model 
144
 as well as the Net Reclassification Improvement (NRI).
143,145
 The NRI, which 
depends mainly on the estimated regression coefficient for the added predictor,
141
 is similar to the 
percent of patients reclassified, but it takes into account movements in the correct direction. Negative 
percentages of the components of the NRI (i.e., event NRI and non-event NRI), as well as a negative 
overall NRI, are interpreted as a net worsening in classification.
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5.4 Results 
 There were 457 cases and 499 controls; the median age of both groups was 41 years. Women 
who underwent hysterectomy were more likely to report tubal ligation, previous myomectomy, 
endometriosis, fibroids, and ovarian cysts; they were also more likely to be black, married, less 
educated, current smokers, parous, and have heavier BMI. OC use was similar among the cases and 
controls (Table 7). 
 Sixty-one cases (13%) and 78 controls (17%) were missing data for one or more variables in 
the risk prediction models (Appendix Table 6). Data on BMI, duration of OC use, endometriosis, 
ovarian cysts, and previous myomectomy were missing less than 3% of the time while 11% of cases 
and 14% of controls were missing data on family history of common, benign gynecologic conditions. 
Participants missing family history data were more likely to be former or current smokers, have less 
than a college degree, and were less likely to report endometriosis or previous myomectomy 
(Appendix Table 7). We performed a sensitivity analysis of the impact of missing family history data 
by coding missing family history as “no” for one full model and as “yes” for another full model; 
results were similar to those from the complete-participant analysis that included a total of 817 
women with non-missing data (Appendix Table 8). 
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 The results for both models A & B were similar and indicated excellent performance, with 
AUC values of 0.85 (Table 8). The discrimination slopes were similar (model A: 0.376; model B: 
0.384) (Figure 3). Both models were also well calibrated; the p-values for the Hosmer-Lemeshow 
GOF tests were 0.2 for both models (Figure 4). The p-values for the GOF test were similar when 
participants were grouped into 20 (p=0.2) and 40 (p=0.3) strata. The slopes of both models’ 
calibration lines were 1.00 and the intercepts were approximately zero (model A: -4.25x10
-8
; model 
B: -1.61x10
-6
). 
 The mean differences between the apparent c statistics from the original models and the 200 
bootstrapped models were 0.0085 for model A and 0.0091 for model B. The bias-corrected AUCs 
were therefore 0.8410 for model A and 0.8445 for model B. 
 The nonparametric test of the difference between the estimated AUCs in models A and B 
yielded p=0.1 (Figure 5). Overall, 16% of participants were reclassified when family history was 
added to the model; only 33% of reclassified cases and 48% of controls were reclassified correctly 
(Table 9). According to the NRI, the net percentage of cases reclassified correctly was <1% and the 
net percentage of controls reclassified correctly was 1%. Hence, the event and non-event NRIs were 
negative (-0.003 and -0.010, respectively), as was the overall NRI (-0.012, 95% CI: -0.041 to -0.015), 
indicating a net worsening in classification. 
5.5 Discussion 
 We developed, a priori, a well-calibrated predictive model for hysterectomy with intention of 
ovarian conservation among premenopausal women that had very good discriminatory power. 
Internal validation resulted in minimal correction of the model’s performance. Adding family history 
of common, benign gynecologic conditions to the model resulted in little to no impact on the model’s 
performance and in fact, a small net worsening of classification. 
 There were minimal missing data and we were able to include an extensive list of predictors 
that have been reported to be associated with hysterectomy or its indications; with 22 degrees of 
freedom in model B, the events-per-variable (EPV) was 18. In simulation studies, no major problems 
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occurred when the EPV was 10 or greater;
127,129
 evidence suggests that the inclusion of nuisance 
predictors (i.e., predictors that don’t substantially contribute to the model) only marginally affects 
discriminatory accuracy.
124
 This is demonstrated by the minimal change in model performance with 
the addition of the family history variable. 
 Although stepwise selection methods for inclusion (or exclusion) of predictors in such 
models are common, several studies have concluded that such methods are deficient, often resulting 
in overestimation of regression coefficients and loss of predictive power.
124,132,133
 Steyerberg et al.
124
 
cautioned against basing the structure of prediction models solely on the data under study, especially 
when the dataset is small, and suggested that previously published or clinically practical 
parameterizations of variables are preferred over classifications that best fit the data. As we selected 
predictors a priori, and examined only the sensitivity of a single model to the inclusion or exclusion 
of a single predictor (family history of benign gynecologic conditions), our analyses did not suffer 
from the typical overfitting that comes from stepwise selection, as evidenced by the negligible 
decrease in the AUC from 0.85 to 0.84 when we adjusted for overfitting optimism. 
 However, given the near-complete absence of model development, nuisance predictors may 
have been included at the cost of degrees of freedom. The study was moderately sized and may 
represent a geographically limited study population. Both cases and controls were from Durham and 
surrounding counties, thus they represent a small area of central North Carolina and may not be 
generalizable to other locations or clinical settings. Additionally, though the control women were 
volunteers, they were recruited from, and likely represent, the source population of women under 
gynecologic care who could potentially have hysterectomies in Durham County. 
 With common and easy-to-define demographic, behavioral, and reproductive factors, we 
showed that we have an ability to predict, with very good discriminatory accuracy, hysterectomy 
among premenopausal women who aim to conserve one or both ovaries. Application of such a model 
throughout a woman’s gynecologic care may lead to earlier and less invasive treatment for common, 
benign gynecologic conditions. Family history of common, benign gynecologic conditions in first-
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degree relatives did not contribute positively to the prediction model. This may be due to the model’s 
already strong performance and the need for a very strong predictor to substantially improve upon the 
AUC. 
141
 In fact, the addition of family history to the model resulted in a slight net worsening of the 
classification, suggesting that it might be counter-productive to use this variable for predictive 
purposes. Additional to its clinical application, information from our ability to predict premenopausal 
hysterectomy may also inform future analyses with respect to missing hysterectomy status or for 
choosing appropriate studies of hysterectomy. 
 The apparent success of this initial prediction model warrants further exploration and 
development in additional datasets representing different populations of premenopausal women. 
Future models could consider additional potential predictors such as symptom index(es) or additional 
medical treatments; prediction of different surgical modalities for hysterectomy could also be 
explored. There is room for improvement upon our preliminary model, including the possibility of 
making it more parsimonious while retaining its strong discriminatory power. As with all prediction 
models, external validation of this model is required before it can be adopted in clinical or other 
settings. 
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Table 7. Baseline characteristics of premenopausal women undergoing hysterectomy with ovarian 
conservation and control women in the Prospective Research on Ovarian Function (PROOF) 
Study, 2004-2007
a
 
 Cases (n=457) Controls (n=499) 
n (%) n (%) 
Age     
 Mean (SD) 40.53 (4.20) 40.12 (4.48) 
 Median 41 41 
 Range (IQR) 30-47 (38-44) 30-47 (37-44) 
Race     
 White 210 (46) 258 (52) 
 Black 236 (52) 214 (43) 
 Other 11 (2) 27 (3) 
Marital Status     
 Single/Never married 82 (18) 128 (26) 
 Married/Living with significant other 283 (62) 260 (52) 
 Divorced/Separated/Widowed 92 (20) 111 (22) 
Education     
 High school graduate or below 112 (25) 86 (17) 
 Some college/trade/tech school 177 (39) 143 (29) 
 College graduate or higher 168 (37) 270 (54) 
Smoking     
 Never 271 (59) 328 (66) 
 Former 88 (19) 88 (18) 
 Current 98 (21) 83 (17) 
BMI at Baseline (kg/m
2
)     
 Mean (SD) 31.07 (7.31) 29.31 (7.54) 
 Median 30.27 27.79 
 Range (IQR) 17.85-55.52 (25.34-35.75) 16.26-66.61 (23.42-34.16) 
      
 Underweight (<18.5) 3 (1) 7 (1) 
 Normal (18.5- <25) 99 (22) 166 (33) 
 Overweight (25- <30) 117 (26) 126 (25) 
 Obese (≥30) 237 (52) 199 (40) 
Oral Contraceptive Use     
 Never 39 (9) 46 (9) 
 Ever 418 (91) 453 (91) 
Years of Oral Contraceptive Use
b
     
 Mean (SD) 8.01 (6.93) 7.45 (6.25) 
 Median 6.00 6.00 
 Range (IQR) 0.08-30.00 (2.00-12.00) 0.08-28.00 (2.50-11.92) 
      
 < 1 year 48 (12) 54 (12) 
 1- <3 years 67 (16) 61 (14) 
 3- <5 years 47 (12) 64 (14) 
 5- <10 years 98 (24) 120 (27) 
 ≥10 years 147 (36) 145 (33) 
Gravidity     
 Never pregnant 50 (11) 105 (21) 
 Ever pregnant 407 (89) 394 (79) 
Number of Full-term Pregnancies
c
      
 Mean (SD) 2.04 (1.10) 1.87 (1.31) 
 Median 2 2 
 Range (IQR) 0-8 (2-3) 0-8 (1-2) 
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 0 23 (6) 52 (13) 
 1 100 (25) 103 (26) 
 2 168 (41) 141 (36) 
 3 82 (20) 66 (17) 
 ≥4 34 (8) 32 (8) 
Reproductive Health (History of)     
 Tubal ligation 210 (46) 135 (27) 
 Fibroids 341 (75) 106 (21) 
 Endometriosis 69 (15) 40 (8) 
 Ovarian cysts 151 (33) 88 (18) 
 Previous myomectomy 43 (9) 17 (3) 
Family History of Benign Gynecologic 
Conditions
d
 257 (63) 189 (44) 
BMI=Body mass index; IQR=Interquartile range; SD=Standard deviation. 
a
 All baseline characteristics were included in the risk prediction models for hysterectomy with the 
exception of gravidity (nulligravid/gravid) and oral contraceptive use (never/ever). Women reporting never 
use of oral contraceptives or nulligravidity were included in the models as 0 years of oral contraceptive use 
and 0 full-term pregnancies, respectively. Numbers (%) are reported for cases and controls except where 
noted. 
b
 Among women who reported ever use of oral contraceptives. 
c
 Among gravid women. 
d
 History of endometriosis, fibroids, or ovarian cysts in mother or sister(s). 
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Table 8. Summary of model performance for the prediction models for hysterectomy with 
ovarian conservation among premenopausal women, without and with family history of 
common, benign gynecologic conditions 
Model AIC Neg 2 Log L AUC AUC SE 
A 832.596 788.596 0.8495 0.0136 
B 824.560 778.560 0.8536 0.0133 
AIC=Akaike’s information criteria; AUC= Area under the curve; AUC SE: Standard error of the area 
under the curve; Neg 2 Log L=Negative 2 Log-Likelihood. 
  
 63 
 
Table 9. Reclassification among all baseline Prospective Research on Ovarian Function 
(PROOF) participants, cases only, and controls only after including family history of common, 
benign gynecologic conditions in the prediction model for hysterectomy with ovarian 
conservation among premenopausal women 
Among All Participants 
(Model B)  
Controls Cases Total % Reclassified 
(Model A) 
Controls 405 19 424 4 
Cases 16 377 393 4 
Among Cases 
(Model B)  
Controls Cases Total % Reclassified 
(Model A) 
Controls 76 11 87 13 
Cases 12 297 309 4 
Among Controls 
(Model B)  
Controls Cases Total % Reclassified 
(Model A) 
Controls 329 8 337 2 
Cases 4 80 84 5 
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Figure 3. Discrimination of the prediction models for hysterectomy with ovarian conservation among 
premenopausal women, without and with family history of common, benign gynecologic conditions. 
Panels (a) and (b) display boxplots for the distributions of predicted probabilities among controls and 
cases for Model A (a) and Model B (b). Panels (c) and (d) display the histograms of risks separated 
for controls (light grey columns) and cases (black columns), separately, for Model A (c) and Model B 
(d). 
  
(b) (a) 
(c) (d) 
 65 
 
(a) 
 
(b) 
 
Figure 4. Calibration of the prediction models for hysterectomy with ovarian conservation among 
premenopausal women, without and with family history of common, benign gynecologic conditions. 
The calibration plot compares observed and predicted risks for deciles of participants, as grouped by 
the Hosmer-Lemeshow Goodness of Fit test, for Models A (panel a) and B (panel b). The ten solid 
dots along the 45-degree line represent the average estimated probability for each decile of 
participants; perfect calibration would be represented by dots that fall directly on the 45-degree line. 
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Figure 5. Receiver operating characteristic curves for the prediction models for hysterectomy with 
ovarian conservation among premenopausal women, without and with family history of common, 
benign gynecologic conditions. The receiver operating characteristic curve plots the true positive rate 
(i.e., sensitivity) on the y-axis against the false positive rate (i.e., 1-specificity) on the x-axis for 
Model A (solid black line) and Model B (dashed red line); the solid diagonal line indicates no 
discrimination. 
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CHAPTER 6. DISCUSSION 
6.1 Recapitulation of aims and results 
 The goal of this dissertation was to explore the relationship between hysterectomy and 
subtypes of epithelial ovarian cancer and to build a multivariate prediction model for premenopausal, 
ovarian-conserving hysterectomy. We accomplished each of the proposed aims through the use of 15 
case-control studies in the Ovarian Cancer Association Consortium and the recent Prospective 
Research on Ovarian Function Study. These aims were: to determine the associations between 
epithelial ovarian cancer and (1) hysterectomy more than two years prior to diagnosis (cases) or 
interview (controls), (2) age at hysterectomy, and (3) time since hysterectomy as well as to (1) 
develop and internally validate a predictive model for premenopausal, ovarian-conserving 
hysterectomy and (2) evaluate the contribution of family history of benign, gynecologic conditions 
among mothers or sisters to the predictive model. 
 Our findings do not support the long-held belief that hysterectomy is protective against 
ovarian cancer. In fact, we found average relative increases in the odds of most subtypes of epithelial 
ovarian cancer with hysterectomy more than two years prior to diagnosis (cases) or interview 
(controls), including hysterectomies prior to age 40 or hysterectomies 30 years or more in the past. In 
support of the published literature, we found an average relative decrease in the odds of invasive clear 
cell epithelial ovarian cancer. 
 We were able to predict ovarian-conserving hysterectomy among premenopausal women 
with very good discriminatory accuracy. The multivariate prediction model was well-calibrated; there 
was good agreement between the predicted probabilities of hysterectomy and the observed outcomes. 
Family history of common, benign gynecologic conditions in the mother or sisters of premenopausal 
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women did not contribute to the performance of the prediction model in an important way, and in 
fact, resulted in a slight net worsening of hysterectomy classification. 
6.2 Strengths  
 One key strength of this research was the opportunity to evaluate the associations between 
aspects of hysterectomy and epithelial ovarian cancer using standardized variable parameterizations 
and the same analytic and statistical approach among women from 15 independent case-control 
studies of ovarian cancer from across the globe. Only one previous study pooled results from multiple 
studies, but it was from an older time period (studies were conducted from 1956 to 1986) when we 
knew far less about the heterogeneous nature of epithelial ovarian cancer; the median years of ovarian 
cancer diagnosis among our studies ranged from 1994 to 2005 and more recent hysterectomies were 
represented. Though rates of hysterectomy have not dramatically changed over the previous several 
decades, surgical approaches have evolved, the rates of concomitant bilateral salpingo-oophorectomy 
are more age-dependent than in previous decades, and women who undergo hysterectomy now may 
have undergone different treatments for their gynecologic condition(s) prior to their hysterectomy that 
did not exist before. Additionally, our study is the largest examination of hysterectomy and epithelial 
ovarian cancer to date; the largest analysis prior to this study included less than half the number of 
women we were fortunate to include. The inclusion of almost 30,000 women allowed us to determine 
the associations between aspects of hysterectomy and subtypes of epithelial ovarian cancer, which 
were not previously studied due to (a) lack of knowledge that risk factors for ovarian cancer may 
differ by subtype and (b) lack of adequate sample size due to ovarian cancer being rare, in general, 
and including only small percentages of each of the non-serous subtypes. 
 Though the number of participants included from the PROOF study was not appreciably 
large, there were minimal missing data and we were able to include an extensive list of 14 variables 
related to demographics, anthropomorphic characteristics, behavioral risk factors, and reproductive 
and medical history that have been reported to be associated with hysterectomy or its indications 
among premenopausal women. Because we selected the prediction model's regressors a priori, there 
 69 
 
was minimal overfitting that is typically a result of data-driven model development being performed 
in the same population as evaluation of the model. Again, though our sample size for this study was 
not on the same scale as our analysis of 30,000 women from 15 studies, we were able to use bootstrap 
methods to internally validate our prediction model. The apparent success of our initial prediction 
model for premenopausal hysterectomy with ovarian conservation represents a solid first step toward 
informing future analyses where hysterectomy status may be missing or where there needs to be 
appropriate selection of women for studies of hysterectomy. Additionally, there may be clinical utility 
in such a prediction model, whereby women may be identified for earlier and hopefully, less invasive 
treatments for their common, benign gynecologic condition(s). 
6.3 Limitations 
 With respect to the prediction model for premenopausal women, one limitation was our 
population of women included in the analysis. Though we are not concerned about the likelihood that 
they represent the population of premenopausal women who may eventually undergo hysterectomy 
for common, benign gynecologic conditions, even though the controls were volunteers who were on 
average, more educated than the source population, they still represent a geographically limited 
population; our findings may not be generalizable to other locations or clinical settings. 
 In our analysis of the associations between aspects of hysterectomy and epithelial ovarian 
cancer, there may have been misclassification of self-reported oophorectomy status. Over time, the 
likelihood of concomitant bilateral salpingo-oophorectomy with hysterectomy has changed such that 
ovarian conservation prior to and during the earlier years of menopause is encouraged. Because of 
that, women who undergo hysterectomy prior to menopause are more likely to retain one or both of 
their ovaries, leaving them at risk for epithelial ovarian cancer. Though misreporting bilateral-
oophorectomy seems unlikely among these women due to the noticeable sequelae of removing both 
ovaries, there may be some misclassification among women whose hysterectomies were performed 
during the perimenopause period or when the indication for hysterectomy involved symptoms that 
mimicked those of menopause (e.g., abnormal uterine bleeding). Women who undergo hysterectomy 
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after menopause are less likely to retain their ovaries, resulting in a small group of women who would 
still be at risk for ovarian cancer. Not only could there be more misclassification of oophorectomy 
status among these women, because the loss of ovarian function has already been experienced, these 
women also likely represent a very particular group of post-menopausal women who retain one or 
both ovaries. The reasons for ovarian conservation among these women may, or may not be related to 
their future ovarian cancer risk. Unfortunately, even with a large sample size of 30,000 women, an 
analysis among these women would be considerably underpowered, even if the appropriate data had 
been collected in the original studies. 
6.4 Public health significance 
 The public health impact of a single study of modest size such as the PROOF study of 
approximately 1,000 women is difficult to evaluate, but our analysis does provide insight into 
premenopausal hysterectomy with ovarian conservation. We were able to predict, with very good 
discriminatory accuracy, premenopausal hysterectomy using easy-to-define variables that could be 
easily collected in a clinical setting. The identification of women "at risk" for future hysterectomy 
could theoretically result in earlier and less-invasive treatments for their gynecologic conditions. 
Though adoption of a prediction model for premenopausal hysterectomy with ovarian conservation in 
a clinical setting cannot and should not occur until additional model development can be done 
prospectively among larger and more diverse groups of women (and subsequently externally 
validated), there is the potential for decreasing the incidence and prevalence of one of the most 
common, and often invasive, surgeries among women in the United States. Our study provides a 
framework around which future prediction models could be developed and validated. 
 Hysterectomy is the most common non-obstetric (e.g., Cesarean delivery) surgery performed 
among women in the United States and impacts approximately 600,000 women each year. More than 
one-third of women will have a hysterectomy by age 60. Like any surgery, there are numerous risks 
and costs associated with having a hysterectomy and downstream consequences of having a 
hysterectomy prior to menopause (e.g., exogenous hormone use) may impact future risk of medical 
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conditions such as ovarian cancer, breast cancer, osteoporosis, and stroke. Ovarian cancer may be 
much rarer than conditions such as breast cancer and osteoporosis, but it is a highly fatal disease for 
which no screening or early detection measures exist. In fact, due to the rarity of ovarian cancer, it is 
unlikely that screening for the disease in the general population, even with a perfectly sensitive and 
specific test, would be beneficial. Most cases are diagnosed at a late stage when five-year survival is 
an abysmal 27%, a fact that has led to ovarian cancer being dubbed the "whispering disease." Though 
questions remain after our analysis of almost 30,000 women from 15 studies across the globe, our 
study provides a reason for critically challenging the status quo in ovarian cancer research and for 
thinking about factors related to hysterectomy that may not have been evaluated at a level of detail 
necessary for identifying direct and indirect effects of exposures and their sequelae. 
6.5 Future research 
 Future research regarding ovarian-conserving hysterectomy among premenopausal women 
should focus, at a much more detailed level, on the factors that predict future hysterectomy so that 
unnecessary hysterectomies might ultimately be avoided; this level of detail may only be available in 
medical records since self-report of complicated medical information is often unknown or 
misclassified. In addition to better understanding the common indications for hysterectomy (fibroids, 
endometriosis, non-specific menstrual disorders), we need to also understand the reasons for and 
outcomes associated with other treatments that may be utilized in place of or prior to the use of 
hysterectomy to treat a condition. Likewise, the downstream consequences of hysterectomy, 
especially prior to menopause, must be studied with far greater detail. It has been shown that women 
who undergo hysterectomy prior to menopause experience menopause earlier than they would have 
without the hysterectomy
121
. This may result in the earlier use of menopausal hormone replacement 
use; the duration of use may also be longer if symptoms of menopause start at an earlier age and 
continue through multiple decades. The risks associated with the types of hormones used, the duration 
of use, and the proximity of use to other risk factors that may impact the incidence or prevalence of 
other diseases are imperative to study. This research will require very detailed information that may 
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only be accurately collected prospectively and/or from medical charts or claims records. The methods 
of analyzing data that relate to different time points along a woman's reproductive health history are 
complicated but more careful consideration of the decisions made by women and their health 
providers could lead to a better understanding and possible prevention of disease such as ovarian 
cancer. 
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APPENDIX. SUPPLEMENTARY TABLES AND FIGURES FOR CHAPTER 4 and 5 
Appendix Table 1. Association between hysterectomy more than two years prior to diagnosis 
(cases) or interview/reference date (controls) and subtypes of invasive serous and mucinous 
epithelial ovarian tumors 
Study 
Low-grade Invasive 
Serous
a
 
High-grade 
Invasive Serous
a
 
LMP Mucinous
b
 
Invasive 
Mucinous
b
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
AUS 0.75 (0.29, 1.93) 1.14 0.88, 1.48 2.00 1.27, 3.16 0.95 0.37, 2.41 
CON N/A N/A 0.72 0.39, 1.33 0.81 0.23, 2.85 3.91 1.33, 11.50 
DOV 0.69 (0.15, 3.18) 1.28 1.00, 1.64 1.12 0.70, 1.78 0.51 0.15, 1.72 
GER N/A N/A 0.67 0.35, 1.28 0.63 0.07, 5.53 0.96 0.33, 2.82 
HAW 
3.58 (0.63, 
20.42) 
1.28 0.85, 1.92 0.82 0.32,2.15 1.12 0.46, 2.75 
HOP 0.33 (0.04, 2.63) 1.25 0.91, 1.71 0.85 0.25, 2.93 0.70 0.24, 2.04 
MAL 1.85 (0.96, 3.57) 1.22 0.77, 1.92 1.11 0.52, 2.35 1.40 0.58, 3.36 
NCO 1.27 (0.57, 2.85) 1.25 0.94, 1.67 1.07 0.51, 2.22 0.70 0.28, 1.74 
NEC 2.11 (0.66, 6.81) 1.02 0.68, 1.54 1.41 0.62, 3.23 0.51 0.12, 2.15 
NTH
c 1.11 (0.11, 
10.99) 
1.30 0.58, 2.93 N/A N/A 1.30 0.42, 4.07 
POL N/A N/A N/A N/A N/A N/A 1.21 0.15, 9.49 
STA
d
 1.26 (0.30, 5.42) 0.81 0.46, 1.42 1.43 0.29, 7.05 0.71 0.19, 2.70 
UCI 2.05 (0.51, 8.25) 1.05 0.63, 1.75 0.47 0.22, 1.01 0.86 0.31, 2.34 
UKO N/A N/A 0.99 0.64, 1.54 N/A N/A 1.47 0.69, 3.14 
USC 1.18 (0.48, 2.93) 1.47 1.14, 1.91 1.18 0.64, 2.19 1.64 0.95, 2.84 
 
Random 
Effects 
 
1.35 (0.92, 1.97) 
 
1.18 (1.06, 1.32) 
 
1.11 (0.82, 1.51) 
 
1.15 (0.88, 1.52) 
𝝉𝟐 0 0 0.05974 0.005291 
95% PI N/A N/A 0.59 to 2.08 0.84 to 1.59 
OEP N/A N/A 33% 3% 
CI=confidence interval; LMP=low malignant potential; N/A=not available/applicable; OEP=opposite effects 
proportion; OR=odds ratio; PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals for the association were estimated by conditional logistic 
regression models stratified by age in 5-year groups and race/ethnicity (non-Hispanic white, Hispanic white, 
black, Asian, other) and adjusted for body mass index in early adulthood (<18.5, 18.5-<25, 25-<30, ≥30), 
parity (0, 1, 2, 3, 4+ full-term births), duration of oral contraceptive use (0, <24 months, 24-<60 months, 60-
<120 months, ≥120 months), tubal ligation (yes/no), and history of breast or ovarian cancer in the mother 
(yes/no). 
b
 Conditional logistic regression models were stratified by age in 5-year groups and race/ethnicity (non-
Hispanic white, Hispanic white, black, Asian, other); models are not adjusted for any additional covariates. 
c
 Models for NTH low-grade and high-grade invasive serous EOC are not adjusted for body mass index in 
early adulthood. 
d
 Models for STA low-grade and high-grade invasive serous EOC are not adjusted for body mass index in 
early adulthood. Model for low-grade invasive serous EOC is not adjusted for endometriosis. 
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Appendix Table 2. Characteristics related to study validity and time/place evaluated as potential sources for heterogeneity of results 
Study 
Cases Controls 
Source 
Median Year 
of Diagnosis 
Mean days 
between 
diagnosis and 
interview 
Timing of 
Sampling 
with Cases 
Eligibility of 
Women Unsure 
of Ovary Status
a
 
Median 
Year of 
Hysterectomy 
Prevalence of 
Hysterectomy 
Age Standardized 
Prevalence of 
Hysterectomy
b
 
AUS Population 2003 161 Concurrent Included 1984 19% 19% 
CON Population 2001 281 Concurrent Excluded 1982 11% 13% 
DOV Population 2005 278 Concurrent Excluded 1982 18% 18% 
GER Population 1994 218 Concurrent Included 1980 24% 24% 
HAW Population 1996 328 Concurrent Excluded 1975 10% 10% 
HOP Population 2005 129 Concurrent Included 1982 17% 15% 
MAL Population 1996 109 Concurrent Included 1979 9% 8% 
NCO Population 2002 185 Concurrent Included 1979 22% 22% 
NEC Population 1997 296 Concurrent Excluded 1977 8% 9% 
NTH Population 2002 2,513 Subsequent Included 1982 13% 12% 
POL Population 2002 95 Concurrent Included 1987 4% 4% 
STA Population 1998 287 Concurrent Excluded 1982 10% 15% 
UCI Population 2000 945 Concurrent Included 1983 25% 26% 
UKO Hospital/Clinic 2005 743 Subsequent Included 1983 19% 15% 
USC Population 1996 275 Concurrent Excluded 1975 11% 12% 
a
 Some studies explicitly excluded potential controls if they were not sure they had at least one intact ovary. Studies that included participants who were 
unsure of their ovary status or who did not give participants the option of a “don’t know” answer are grouped together. 
b
 The standard population used was the arithmetic mean of the un-weighted distribution of ages in each study’s control group (age groups: 18-44, 45-64, 
65+). 
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Appendix Table 3. Counts of hysterectomies that occurred at or prior to diagnosis (cases) or interview/reference date 
(controls) according to study and outcome 
Study 
Hysterectomy At or Prior to Diagnosis 
(Cases) or Interview/Reference Date 
(Controls)
a
 
Hysterectomy in the First Year 
Prior to Diagnosis (Cases) or 
Interview/Reference Date 
(Controls)
b
 
Hysterectomy in the Second Year 
Prior to Diagnosis (Cases) or 
Interview/Reference Date 
(Controls)
c
 
Cases Controls Cases Controls Cases Controls 
AUS 327/1420 (23) 291/1488 (20) 0/327 (0) 1/291 (<1) 11/327 (3) 9/291 (3) 
CON 116/476 (24) 61/549 (11) 23/116 (20) 1/61 (2) 27/116 (23) 1/61 (2) 
DOV 319/1576 (20) 358/1849 (19) 5/319 (2) 7/358 (2) 5/319 (2) 9/357 (3) 
GER 53/258 (21) 137/533 (26) 3/53 (6) 4/137 (3) 0/53 (0) 3/137 (2) 
HAW 113/896 (13) 114/1104 (10) 1/113 (1) 4/114 (4) 2/113 (2) 1/114 (1) 
HOP 151/771 (20) 309/1804 (17) 4/151 (3) 0/309 (0) 2/151 (1) 11/309 (4) 
MAL 99/755 (13) 146/1564 (9) 0/99 (0) 4/146 (3) 0/99 (0) 3/146 (2) 
NCO 271/1092 (25) 248/1081 (23) 17/271 (6) 2/248 (1) 5/271 (2) 4/248 (2) 
NEC 92/1119 (8) 102/1243 (8) 0/92 (0) 1/102 (1) 2/92 (2) 1/102 (1) 
NTH 177/255 (69) 82/594 (14) 139/177 (79) 2/82 (2) 2/177 (1) 1/82 (1) 
POL 216/293 (74) 51/1101 (5) 207/216 (96) 1/51 (2) 1/216 (<1) 3/51 (6) 
STA 78/660 (12) 61/566 (11) 18/78 (23) 3/61 (5) 2/78 (3) 3/61 (5) 
UCI 125/589 (21) 159/569 (28) 0/15 (0) 10/159 (6) 3/15 (20) 4/159 (3) 
UKO 342/603 (57) 201/1033 (19) 232/342 (68) 0/201 (0) 18/342 (5) 3/201 (1) 
USC 287/1736 (17) 211/1809 (12) 3/287 (1) 4/211 (2) 5/287 (2) 2/211 (1) 
All 2766/12499 (22) 2531/16887 (15) 652/2766 (24) 44/2531 (2) 85/2766 (3) 58/2531 (2)  
a
 The counts and percentages shown represent the proportion of women who reported hysterectomy at the same age, or an earlier age, 
as their age at diagnosis (cases) or age at interview/reference date (controls). 
b
 The counts and percentages shown represent the proportion of hysterectomies where the difference between age at 
diagnosis/interview and age at hysterectomy is less than or equal to 1. 
c
 The counts and percentages shown represent the proportion of hysterectomies where the difference between age at 
diagnosis/interview and age at hysterectomy is greater than 1 and less than or equal to 2. 
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Appendix Table 4. Sensitivity analysis of the association
a
 between hysterectomy
b 
and low malignant potential epithelial ovarian tumors 
Study 
At or Prior 
More Than One Year 
Prior 
More Than Two Years 
Prior 
OR 95% CI OR 95% CI OR 95% CI 
AUS 1.76 1.23, 2.53 1.78 1.24, 2.55 1.85 1.28, 2.67 
CON 4.41 2.54, 7.64 3.88 2.20, 6.86 1.60 0.81, 3.16 
DOV 1.35 1.00, 1.83 1.36 1.00, 1.85 1.40 1.03, 1.90 
GER 0.81 0.21, 3.09 0.50 0.11, 2.37 0.52 0.11, 2.47 
HAW 1.31 0.72, 2.39 1.42 0.77, 2.61 1.42 0.77, 2.62 
HOP 2.13 1.20, 3.78 2.13 1.20, 3.78 2.25 1.26, 4.00 
MAL
c
 1.18 0.71, 1.96 1.22 0.73, 2.02 1.25 0.75, 2.08 
NCO 1.23 0.80, 1.91 1.11 0.71, 1.74 1.13 0.72, 1.77 
NEC 1.44 0.85, 2.46 1.47 0.86, 2.50 1.52 0.89, 2.60 
STA
d
 1.32 0.64, 2.71 1.07 0.49, 2.35 1.02 0.45, 2.32 
UCI 0.39 0.22, 0.69 0.46 0.25, 0.83 0.44 0.24, 0.81 
USC 1.50 1.03, 2.18 1.46 1.00, 2.14 1.44 0.98, 2.11 
       
Random 
Effects 
1.40 0.98, 1.99 1.37 0.89, 1.91 1.32 1.02, 1.71 
?̂?𝟐 0.2195 0.1656 0.07088 
95% PI 0.46 to 4.21 0.52 to 3.61 0.69 to 2.52 
OEP 21% 22% 15% 
CI=confidence interval; N/A=not available; OEP=opposite effects proportion; OR=odds ratio; 
PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals for the association between hysterectomy and all 
LMP tumors combined were estimated by conditional logistic regression models stratified by 
age in 5-year groups and race/ethnicity (non-Hispanic white, Hispanic white, black, Asian, 
other) and adjusted for body mass index in early adulthood (<18.5, 18.5-<25, 25-<30, ≥30), 
parity (0, 1, 2, 3, 4+ full-term births), duration of oral contraceptive use (0, <24 months, 24-
<60 months, 60-<120 months, ≥120 months), tubal ligation (yes/no), and history of breast or 
ovarian cancer in the mother (yes/no). 
b
 The exposed group is defined in three different ways for the sensitivity analysis: (1) 
hysterectomy at or prior to diagnosis (cases) or interview/reference date (controls), (2) 
hysterectomy more than one year prior to diagnosis (cases) or interview/reference date 
(controls), and (3) hysterectomy more than two years prior to diagnosis (cases) or 
interview/reference date (controls). 
c
 Models for MAL are not adjusted for history of breast or ovarian cancer in the mother due to 
missing data. 
d 
Models for STA are not adjusted for body mass index in early adulthood or endometriosis. 
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Appendix Table 5. Sensitivity analysis of the association
a
 between hysterectomy
b
 
and invasive epithelial ovarian cancer 
Study 
At or Prior 
More Than One 
Year Prior 
More Than Two Years 
Prior 
OR 95% CI OR 95% CI OR 95% CI 
AUS 1.23 1.00, 1.53 1.24 1.00, 1.54 1.20 0.96, 1.49 
CON 2.31 1.54, 3.47 1.61 1.05, 2.47 1.28 0.82, 2.00 
DOV 1.24 1.01, 1.51 1.26 1.03, 1.54 1.27 1.03, 1.55 
GER 0.82 0.53, 1.26 0.79 0.51, 1.22 0.83 0.54, 1.29 
HAW 1.30 0.95, 1.77 1.35 0.98, 1.85 1.33 0.96, 1.82 
HOP 1.23 0.96, 1.56 1.19 0.93, 1.51 1.21 0.94, 1.54 
MAL
c
 1.47 1.08, 2.00 1.51 1.11, 2.06 1.55 1.14, 2.12 
NCO 1.20 0.95, 1.52 1.08 0.85, 1.38 1.07 0.84, 1.37 
NEC 1.05 0.74, 1.47 1.06 0.75, 1.49 1.05 0.74, 1.48 
NTH
d
 14.33 8.88, 23.15 1.24 0.71, 2.16 1.27 0.73, 2.22 
POL
e
 65.75 40.25, 107.40 0.59 0.26, 1.32 0.54 0.23, 1.27 
STA
f
 1.01 0.65, 1.55 0.71 0.44, 1.13 0.72 0.45, 1.17 
UCI 0.78 0.52, 1.17 0.93 0.62, 1.41 0.96 0.63, 1.45 
UKO 5.86 4.39, 7.81 1.38 1.01, 1.89 1.21 0.88, 1.67 
USC 1.44 1.16, 1.79 1.46 1.18, 1.82 1.44 1.15, 1.79 
       
Random 
Effects 
2.05 1.04, 4.03 1.21 1.07, 1.36 1.19 1.08, 1.32 
?̂?𝟐 1.436 0.006593 0.001531 
95% PI 0.14 to 29.79 0.98 to 1.49 1.05 to 1.36 
OEP 27% 1% <1% 
  
 Excluding NTH, POL, and UKO
g
 
Random 
Effects 
1.23 1.06, 1.43 1.20 1.06, 1.37 1.20 1.07, 1.34 
?̂?𝟐 0.01922 0.008824 0.003232 
95% PI 0.87 to 1.74 0.94 to 1.54 1.01 to 1.42 
OEP 7% 2% <1% 
CI=confidence interval; N/A=not available; OEP=opposite effects proportion; OR=odds ratio; 
PI=prediction interval. 
a
 Odds ratios and 95% confidence intervals for the association between hysterectomy and all 
invasive epithelial ovarian cancers combined were estimated by conditional logistic 
regression models stratified by age in 5-year groups and race/ethnicity (non-Hispanic white, 
Hispanic white, black, Asian, other) and adjusted for body mass index in early adulthood 
(<18.5, 18.5-<25, 25-<30, ≥30), parity (0, 1, 2, 3, 4+ full-term births), duration of oral 
contraceptive use (0, <24 months, 24-<60 months, 60-<120 months, ≥120 months), tubal 
ligation (yes/no), and history of breast or ovarian cancer in the mother (yes/no).  
b
 The exposed group is defined in three different ways for the sensitivity analysis: (1) 
hysterectomy at or prior to diagnosis (cases) or interview/reference date (controls), (2) 
hysterectomy more than one year prior to diagnosis (cases) or interview/reference date 
(controls), and (3) hysterectomy more than two years prior to diagnosis (cases) or 
interview/reference date (controls).  
c
 Models for MAL all LMP tumors combined are not adjusted for history of breast or ovarian 
cancer in the mother due to missing data. 
d 
Models for NTH are not adjusted for body mass index in early adulthood. 
e
 Models for POL are not adjusted for endometriosis. 
f
 Models for STA are not adjusted for body mass index in early adulthood or endometriosis. 
g 
69%, 74%, and 57% of the cases from the NTH, POL, and UKO studies, respectively, 
reported ever having a hysterectomy (see Appendix Table 3). As these percentages are much 
higher than the percentage of cases from other studies reporting hysterectomy, and from the 
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general populations that these studies represent, we decided to perform sensitivity analyses 
that (a) defined our exposure using different time periods and (b) excluded these studies from 
the pooled results. 
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Appendix Table 6. Accounting of missing data among women undergoing hysterectomy and 
control women in the PROOF Study, 2004-2007
a
 
 Cases (n=457) Controls (n=499) 
 N (%) N (%) 
Age 0 (0) 0 (0) 
Race 0 (0) 0 (0) 
Marital Status 0 (0) 0 (0) 
Education 0 (0) 0 (0) 
Smoking 0 (0) 0 (0) 
BMI at Baseline 1 (<1) 1 (<1) 
Duration Oral Contraceptive Use 11 (3) 9 (2) 
Full-term Pregnancies 0 (0) 0 (0) 
Tubal ligation 0 (0) 0 (0) 
Fibroids 0 (0) 3 (1) 
Endometriosis 1 (<1) 3 (1) 
Ovarian cysts 0 (0) 2 (<1) 
Previous myomectomy 1 (<1) 0 (0) 
Family History of Benign Gynecologic Conditions
b
 50 (11%) 68 (14%) 
BMI=Body mass index. 
a
 Sixty-one cases (13%), representing 44% of the participants with missing data, and 78 controls (17%), 
representing 56% of the participants with missing data, are missing data for one or more variables in 
the risk prediction model. Fifty-eight cases and 72 controls are missing data for one variable, three 
cases and five controls are missing data for two variables, and one control is missing data for four 
variables. 
b
 History of endometriosis, fibroids, or ovarian cysts in mother or sister(s). 
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Appendix Table 7. Baseline characteristics, by missingness of family history of common, benign 
gynecologic conditions, of participants in the PROOF Study, 2004-2007
a
 
 Missing FamHx (n=118) Not Missing FamHx 
(n=838) 
N (%) N (%) 
Age     
 Mean (SD) 40.25 (4.68) 40.32 (4.31) 
 Median 41 41 
 Range (IQR) 30-47 (37-44) 30-47 (37-44) 
Race     
 White 55 (47) 413 (49) 
 Black 58 (49) 392 (47) 
 Other 5 (4) 33 (4) 
Marital Status     
 Single/Never married 28 (24) 182 (22) 
 Married/Living with significant other 68 (58) 475 (57) 
 Divorced/Separated/Widowed 22 (19) 181 (22) 
Education     
 High school graduate or below 33 (28) 165 (20) 
 Some college/trade/tech school 33 (28) 287 (34) 
 College graduate or higher 52 (44) 386 (46) 
Smoking     
 Never 62 (53) 537 (64) 
 Former 27 (23) 149 (18) 
 Current 29 (25) 152 (18) 
BMI at Baseline (kg/m
2
)     
 Mean (SD) 29.73 (8.50) 30.21 (7.33) 
 Median 27.93 29.06 
 Range (IQR) 16.41-55.52 (23.23-34.53) 16.26-66.61 (24.53-34.78) 
      
 Underweight (<18.5) 3 (3) 7 (1) 
 Normal (18.5- <25) 36 (31) 229 (27) 
 Overweight (25- <30) 32 (27) 211 (25) 
 Obese (≥30) 47 (40) 389 (47) 
Oral Contraceptive Use     
 Never 11 (9) 74 (8) 
 Ever 107 (91) 764 (92) 
Years of Oral Contraceptive Use
b
     
 Mean (SD) 7.03 (7.16) 7.02 (6.59) 
 Median 5.00 5.00 
 Range (IQR) 0.00-28.00 (0.50-11.08) 0.00-30.00 (1.00-11.00) 
      
 < 1 year 19 (19) 83 (11) 
 1- <3 years 12 (12) 116 (15) 
 3- <5 years 12 (12) 99 (13) 
 5- <10 years 27 (26) 191 (26) 
 ≥10 years 32 (31) 260 (31) 
Gravidity     
 Nulligravid 19 (16) 136 (16) 
 Gravid 99 (84) 702 (84) 
Number of Full-term Pregnancies
c
     
 Mean (SD) 1.91 (1.24) 1.97 (1.21) 
 Median 2 2 
 Range (IQR) 0-6 (1-3) 0-8 (1-3) 
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 0 19 (16) 136 (16) 
 1 23 (19) 125 (15) 
 2 26 (22) 195 (23) 
 3 25 (21) 161 (19) 
 ≥4 25 (21) 221 (26) 
Reproductive Health (History of)     
 Tubal ligation 43 (36) 302 (36) 
 Fibroids 52 (45) 395 (47) 
 Endometriosis 8 (7) 101 (12) 
 Ovarian cysts 25 (21) 214 (26) 
 Previous myomectomy 5 (4) 55 (7) 
BMI=Body mass index; IQR=Interquartile range; SD=Standard deviation. 
a
 All baseline characteristics are included in the risk prediction model for hysterectomy with the exception of 
gravidity (nulligravid/gravid) and oral contraceptive use (never/ever). Women reporting never use of oral 
contraceptives or nulligravidity will be included in the model as 0 years of oral contraceptive use and 0 full-
term pregnancies, respectively. Numbers (%) are reported for cases and controls except where noted. 
b
 Among women who reported ever use of oral contraceptives. 
c
 Among gravid women. 
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Appendix Table 8. Sensitivity analysis of model performance for the prediction models for 
hysterectomy with ovarian conservation among premenopausal women where the n=118 
observations missing family history of common, benign gynecologic conditions are recoded 
as no or yes (presence of family history of common, benign gynecologic conditions) 
Model AIC Neg 2 Log L AUC AUC SE 
Recoded "No" 946.377 900.377 0.8465 0.0128 
Recoded "Yes" 950.292 904.292 0.8452 0.0129 
AIC=Akaike’s information criteria; AUC= Area under the curve; AUC SE: Standard error of the area 
under the curve; Neg 2 Log L=Negative 2 Log-Likelihood. 
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